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hnRNP A1 is one of the most abundant and ubiquitously expressed member of  
hnRNPs (Heterogenous Nuclear Ribonucleoproteins) family of proteins that play multiple 
roles in gene expression by participating in major steps in the processing of nascent RNA 
transcripts 1. It is involved in mRNA biogenesis mechanisms such as the transcription, 
splicing, stability, export and translation of cellular and viral transcripts. The functions of 
hnRNP A1 extend to the processing of microRNAs, telomere maintenance and DNA repair 1.  
Our previous studies have shown that hnRNP A1 had reduced protein level and increased 
cytoplasmic accumulation in senescent human diploid fibroblasts 2,10. Our preliminary data 
showed that HDM2 mRNA associates with hnRNP A1 in IMR-90 cells. We have also 
observed that alterations of hnRNP A1 expression can modulate HDM2 mRNA levels.  
HDM2 expression must be regulated in normal and stressed cells to maintain normal p53 
levels. Numerous proteins interact with HDM2 to regulate its expression 7. Failure to regulate 
HDM2 results in aberrant HDM2 expression leading to deregulation of the p53 activity.  
Consequently, adequate levels of HDM2 are maintained through transcriptional, post-
transcriptional and post-translational regulation. In this thesis, we have examined how hnRNP 
A1 potentially modulates HDM2 gene expression given our preliminary observation that the 
levels of HDM2 mRNA increased with the down-regulation of hnRNP A1 and decrease with 
! ! 9!
the overexpression of hnRNP A1 (Shimada, N and K, Hubbard.). In this research project, we 
demonstrated that overexpression of GFP-A1 significantly decreases the pre-HDM2 mRNA 
levels compared to IMR-90 cells transiently transfected with the empty vector control, GFP-
EV. We also observed a decreased in HDM2 and a concomitant increase in p53 protein levels 
with the overexpression of hnRNP A1. In addition, we also found a significant increased in 
both p14 mRNA and protein levels with the overexpression of GFP-A1 suggesting that p14 
ARF is induced via hnRNP A1. p14 ARF has been shown to directly interact with HDM2 and 
induced its degradation leading to the stabilization of p53. These results suggest that hnRNP 
A1 is negatively regulating the expression of HDM2. Our studies also show that hnRNP A1 
directly interacts with HDM2 mRNA at a region corresponding to its 3’ UTR. The results 
from this study demonstrate that hnRNP A1 has a novel role in participating in the regulation 
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1a. Importance of gene regulation 
                 Regulation of gene expression is a highly complex and tightly regulated process. It is 
mainly regulated at the transcriptional, post-transcriptional, translational and post-translational 
level. These processes affect the levels of the protein encoded by the mRNA. As soon as the 
mRNA is produced by RNA Pol II, it is rapidly bound by RNA binding proteins forming 
ribonucleoprotein complexes, the substrates for mRNA processing 1. These RNA binding 
proteins regulate and couple the post-transcriptional steps of gene expression. The current 
view of gene expression indicates that the steps regulating gene expression are physically and 
functionally connected. This continuous process provides a more efficient transfer of 
information between the different stages linked to transcription. The C-terminal domain 
(CTD) of RNA Polymerase II has been suggested to participate in the coupling of the different 
steps of RNA processing by providing a platform for the different factors mediating these 
processes 14.  
 
1b. Gene expression and RNA processing 
Eukaryotic gene expression begins when a gene is transcribed into a RNA transcript 
by RNA polymerase II, which takes place in the nucleus. The initial product of transcription is 
pre-mRNA. This nascent transcript contains introns, exons and other sequences, which 
undergo series modifications to become a mature transcript. These modifications include the 
addition of a 5’ 7 methyl-guanosine cap (cap), splicing, and the addition of the poly (A) tail.  
These three processes must occur before the RNA can be exported to the cytoplasm. The 
mRNA that is successfully exported to the cytoplasm is the mature mRNA that is translated 
into a protein via the ribosomes. All these processes of pre-mRNA processing would have not 
! ! M!
taken place without the presence of hnRNPs. Heterogenous nuclear ribonucleoproteins 
(hnRNPs) are RNA binding proteins directly involved in the maturation of the nascent 
transcripts. Besides being involved in the pre-mRNA processing steps, they also take part in 
transport, localization, translation and stability of mRNAs 12.   
          The steps involved in the mRNA processing are coupled to the process of transcription.  
For instance, the carboxyl terminal domain of RNA polymerase II has been shown to play a 
key role in linking transcription with mRNA processing specifically by acting as a protein 
scaffold. hnRNPs and other processing factors are recruited to the pre-mRNA in complex with 
the Carboxy terminal domain of RNA pol II 13,14. The fact that hnRNPs associate with mRNA 
from the beginning of transcription to the mature cytoplasmic mRNA demonstrate their 
importance in the gene expression pathway  
1c. pre-mRNA splicing  
 
Figure 1.1. Splice site elements (adapted from Smith and Vacarcel, 2000). Consensus splice 
site elements for a typical metazoan intron (R, purine;Y, pyrimidine; N, any nucleotide).  The 
minimal distances between the 5’ splice site and branch point, and between the 3’ splice site 
and branch point are indicated. 
      
          Splicing is one of the steps in processing of pre-mRNA which involves the removal of 
intervening sequences also known as introns. The process of splicing takes place after the 
consensus sequences, the 5’ splice site, branch point and 3’ splice site are recognized by the 
Chapter 1: Introduction 
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spliceosome which is a large multicomponent ribonucleoprotein complex (Figure 1.1). These 
consensus sequences allow the chemical reaction of splicing to take place via two 
transesterification reactions (Figure 1.2). Nucleophilic attack of the 5'ss by the 2'OH of the BP 
adenosine and the first transesterification reaction results in a free 5' exon and a lariat 
containing the intron sequences plus the 3' exon 15. The 3'OH of the freed 5' exon then attacks 
the 3'ss and the ensuing transesterification reaction results in fusion of the 5' and 3' exons and 





Figure 1.2. Splicing takes place in two transesterification reactions (adapted from Black, 
2003). The first reaction results in a free 5’ exon and the intron and 3’exon contained in a 
lariat structure. After the second transesterification reaction the two exons are ligated 
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Figure 2. The assembly of the spliceosome  
Sanford JR, Caceres JF. Pre-mRNA splicing: life at the centre of the central dogma. J Cell 
Sci. 2004 Dec 15;117(Pt 26):6261-3. 
  
          The introns of pre-mRNA are removed by the spliceosome, a macromolecular complex, 
that is composed of five core small nuclear ribonucleoproteins (snRNPs, U1, U2, U4, U5, U6) 
16,17. The stepwise assembly of the spliceosome onto the pre-mRNA requires the presence of 
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several auxiliary splicing factors 18. The assembly of the spliceosome begins with the 
recognition of the 5 and 3 splice sites by the U1 snRNP and the heterodimeric U2 snRNP 
auxiliary factor (U2AF), respectively, forming the E (early) complex. This is follow by the 
recruitment of the U2 snRNP to the BP, an ATP-dependent step, which results in the 
generation of the A complex. Finally the U4, U5 and U6 snRNPs join the pre-spliceosome to 
form the B complex 13,18. Following a series of RNA-RNA and protein-RNA rearrangements, 
the catalytic C complex is formed resulting in the release of U1 and U4 13,18 as shown in 
Figure 2. This step completes the assembly of the spliceosome and now ready to complete 
another round of splicing.  
1.2 Post-transcriptional gene regulation 
          As previously mentioned gene expression can be regulated at the level of transcription, 
post-transcription and translation. The different layers of gene regulation can be divided into 
two main categories: the transcriptional and post-transcriptional control. A lot of studies have 
been primarily devoted to transcriptional control through single gene studies 72, transcription 
factor binding studies and identification of regulatory sequence elements 73. However, 
recently a great emphasis of gene regulation mechanism has been concentrated in post-
transcriptional regulation given its significant impact in mammalian physiology and 
pathology. This type of regulation occurs after the gene is transcribed by RNA polymerase II.  
It begins with the processing of mRNA (polyadenylation, capping and splicing), mRNA 
export and localization, mRNA decay and translation. It also allows the cell to control the 
translation of a given mRNA into a protein. Therefore, translation and translation control are 
important components for post-transcriptional gene expression regulation. In addition to this, 
it also permits the cell to make the necessary changes in gene expression much faster than by 
! ! P!
transcriptional regulation alone. There are two main groups reported to participate in post-
transcriptional regulation. These groups of posttranscriptional regulators consist of the RNA 
binding proteins and noncoding RNAs 1,74. The RNA binding proteins regulate gene 
expression by contributing to RNA splicing, transport, mRNA stability, RNA storage, non-
coding RNAs and translational regulation 1.  
1.3 The role of RNA binding proteins in gene regulation 
          RNA binding proteins play a key role in post-transcriptional regulation of gene 
expression. Most of these proteins bind the RNA transcripts specifically at the 3’ or 5’ UTR 
end  58. For instance, when RNA binding proteins bind to the pre-mRNA close to the 3’ or 5’ 
splice sites, they can either hide or recruit the splicing machinery to these sites 1. By binding 
to these sites, they can control alternative splicing which ultimately affects the sequence of the 
final protein product. The process of alternative splicing is important because it induces the 
production of alternate products by external or internal stimuli. Besides playing a key role in 
splicing, RNA binding proteins also function to make sure that the splicing process has been 
completed so that the spliced mRNA can be release for export 75. This mechanism of mRNA 
surveillance is accomplished by a protein complex also known as Exon Junction Complex 
(EJC) that forms on a pre-mRNA strand at the junction of two exons. The EJC complex is 
deposited about 20-24 nucleotides from the 5’ end upstream of the splice junction, the 
location where two exons are joined 75. This type of mRNA surveillance ensures that mRNA 
transcripts with a premature codon, damage or are aberrantly spliced are degraded in the 
nucleus by a mRNA degradation pathway 75. A poly a tail is added to the 3' end of most 
eukaryotic mRNA by poly-A polymerase mainly to protect the RNA from degradation. The 
polyadenylation process is carried out by specific RNA binding proteins, polyA polymerase.  
! ! Q!
It needs to interact with the other RNA binding proteins, CPSF and nuclear polyA binding 
protein to activate its activity 76. 
1.3a Role of RNA binding proteins in mRNA export 
          The export of translation ready mRNA is another example where the participation of 
RNA binding proteins is really important. mRNA export begins with the generation of a 
cargo-carrier complex in the nucleus. This is followed by the translocation of the complex 
through the nuclear pore complex. The final step is the release of the mRNA cargo in 
cytoplasm and the recycling of the carrier. The export of mRNA is mediated by RNA binding 
protein NXf1 (nuclear RNA export factor 1) also known as TAP 1,76. Previous studies have 
demonstrated that TAP binds to the constitutive transport element (CTE), an element found to 
be necessary for the export of retroviral transcripts 77. In other studies it was also 
demonstrated that the overexpression of TAP in xenopus laevis oocytes permitted the export 
of inefficiently exported transcripts suggesting that TAP has a direct role in mRNA export 
76,77. 
1.3b Role of RNA binding proteins in mRNA turnover   
          RNA binding proteins participate in other types of RNA processing mechanism such as 
directly controlling mRNA turnover while modulates the steady state concentrations of 
specific mRNAs 76,81. For example, RNA binding proteins that bind to RNA molecules on 
specific cis sites, can recruit or hide endonuclease sensitive sites. This consequently alters the 
stability and secondary structure of the RNA molecule. The dynamic balance of ongoing 
transcription and degradation processes maintains the steady-state level of mRNA transcript 
81. The process of mRNA degradation takes place in both the nucleus and cytoplasm since 
mRNA degradation pathways exist in both compartments. As already discussed above, the 
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Exon junction complex selectively degrades mRNA transcripts that are incorrectly spliced 
78,79. In the cytoplasm, there is a Nonsense mediated mRNA decay pathway which recognizes 
and degrades aberrant transcripts containing premature stop codons. In addition to the NMD 
mediated pathway, other cytoplasmic mRNA decay pathway mediating the mRNA turnover 
79,81.  
For example, endonucleolytic or exonucleolytic pathways can control the decay of 
mRNA in the cytoplasm differently 78,79. Exonucleolytic degradation is often begun by 
deadenylation dependent decay carried out by deadenylating nuclease (DAN), which degrades 
the poly A tail of mRNA 81. Once the poly A tail reaches about 20-30 nt, removal of the 5’cap 
structure is followed by the decapping enzymes, Dcp1 and Dcp2 82,83. The decapped 
intermediate transcripts will be degraded from their 5’ end by the exonuclease XRN1 78,82. 
The exosome has been observed to degrade the transcripts from 3’ ends even before 
decapping. The mRNA that is actively being translated is less subjected to DAN mediated 
decay thus ensuring a longer half-life for transcripts that are often translated 82. 
          A more specific type mRNA degradation mechanism is the endonucleolytic pathway 
also occurring in the cytoplasm. In this type of mRNA degradation, specific endonucleases 
recognize nucleotide sequences located in the 5’ or 3’ UTR regions of the mRNA 81. Once the 
transcript is cleave, decapping takes place immediately followed by decay of the transcript by 
5’ 3’ and 3’5’ exonucleases 81. This type of mRNA degradation is often used by cells 
requiring genes with a high turnover rate such as the proto-oncogenes, cytokines or cell cycle 
genes.   
1.3c Translational Control 
! ! &%!
          Regulation of gene expression at the translational level can occur in response to cellular 
stress without going through all the upstream processes of gene expression such as 
transcription, mRNA processing or mRNA export. Translation regulation is often reversible, 
as it is meditated by post-translational modification such as phosphorylation of initiation 
factors 84. The translation of mRNA into a protein in eukaryotes can occur in two ways; Cap-
dependent translation 85 and the IRES-dependent translation (Cap-independent) 86. Protein 
synthesis or translation is divided into 3 major steps: initiation, elongation and termination. 
The rate limiting step in translation is the initiation step. It is not surprising that most of the 
control of translation is mediated at the level of initiation 87. Cap-dependent translation 
depends on the recognition of the 5’ 7-methylguanosine cap by eukaryotic initiation factor 4E 
(eIF4E) and 5’ cap binding protein (CBP) 85. Initiation factors eIF4A, eIF4B, and eIF4G 
participate in translation by controlling the secondary structure and recruiting the small (40S) 
ribosomal unit 85. It has been documented that regions of highly ordered secondary structures 
are found in some 5’ UTRs. These regions prevent the scanning of the small ribosomal 
subunit 88. RNA binding proteins have been proposed to potentially modulate the initiation of 
cap-dependent translation because they could affect secondary structure or form steric 
hindrance in the 5’ UTR. For instance, when RNA binding proteins bind to mRNA, they 
could prevent translational initiation, induce premature translational termination, or promote 
the recruitment of the translational machinery 87,88.  
Under cellular stress conditions, translation of certain genes such as the housekeeping 
genes is down-regulated 86. On the other hand, the translation of stress related genes is up-
regulated. As a result of these stressful conditions, translation initiation occurs in a cap-
independent manner through internal ribosomal entry sites (sites). These IRES are heavily 
! ! &&!
structured sequence elements often found in the 5’ UTR but can also be located in the coding 
region 86. In cap-independent translation, the initiation factor eIF4G interacts directly with the 
IRES sequence inducing the recruitment of the 40S subunit. IRES elements are found in 
specific subset of mRNAs involved in growth control, cell cycle and control of apoptosis 85.  
RNA binding proteins have been shown to participate in the translation control of certain 
genes. hnRNP A1 has been shown to bind to internal ribosomal entry site sequences (IRES) 
and can either promote or repress the IRES-mediated translation 1. For instance, it has been 
demonstrated that the assembly of hnRNP A1 onto IRESs of human fibroblast growth factor 2 
(FGF-2) mRNA resulted in the enhancement of its IRES-mediated translation 1. Although the 
exact mechanism of hnRNP A1-mediated inhibition of IRES acitivity is not known, it has 
been proposed to involved post-translational modification of hnRNP A1 and/or interacting 
proteins 1,123.  
1.4 Ras-Raf-MEK-ERK PATHWAY 
          Cells respond to a large number of extracellular signals that induce changes in gene 
expression 91. These changes in gene expression promote adequate physiological responses 91.  
The signals or stimuli that cells respond to could be mitogens, growth factors or cytokines.  
Upon binding to their appropriate surface receptor, ligands activate numerous intracellular 
pathways such as the Ras-Raf-ERK signaling cascade (Figure 3). These signals can be linked 
to gene promoters and transcription factors leading to the regulation of inducible cellular 
processes such as transcription and translation 89,91. Some extracellular signals are transmitted 
to their target via intracellular kinases. These kinases amplify the original message by 
phosphorylating and activating other kinases 89. This form of intracellular signaling network 
consists of the mitogen-activated protein kinase cascade, an evolutionary conserved pathway 
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among eukaryotes 90,91. Transmission of signals via these cascades is usually triggered by 
activation of a small G-protein (Ras) and then as previously mentioned this is followed by 
sequential activation of cytoplasmic protein kinases 89,90,91. So far four distinct MAPK 
cascades (ERK, JNK, p38 and ERK5) have been examined in detailed 89. These cascades are 
extracellular signal-regulated kinase 1 and 2 (ERK1/2; 92,93), c Jun N-terminal kinase (JNK, 
94), p38 MAPK !, ", #, and $ 95, and ERK5 96. The ERK1/2 signaling pathway has been shown 
to play a key role in proliferation and differentiation 89,90,91.   
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Figure 3. Overview of the Ras-Raf-MEK-ERK pathway 
McCubrey JA et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant 
transformation and drug resistance. Biochim Biophys Acta. 2007 Aug;(8):1263-84. Epub 
2006 Oct 7. Review. 
1. Introduction
1.1. Overview of the Ras/Raf/MEK/ERK signaling
The Ras/Raf/MEK/ERK cascade couples signals from cell
surface receptors to transcription factors, which regulate gene
expression. Furthermore, this cascade also regulates the activity
of many proteins involved in apoptosis. A diagrammatic
overview of the Ras/Raf/MEK/ERK pathway is presented in
Fig. 1. This pathway is often activated in certain tumors by
chromosomal translocations such as BCR-ABL, mutations in
cytokine receptors such as Flt-3, Kit, Fms or overexpression of
wild type or mutated receptors, e.g., EGFR. The Raf/MEK/ERK
pathway also has profound effects on the regulation of apoptosis
by the post-translational phosphorylation of apoptotic regula-
tory molecules including Bad, Bim, Mcl-1, caspase 9 and more
controversially Bcl-2. This pathway has diverse effects which
can regulate cell cycle progression, apoptosis or differentiation
[1]. A survey of the literature documents the daily increase in
the complexity of this pathway, as there are multiple members
of the kinase, transcription factor, apoptotic regulator and
caspase executioner families, which can be activated or
inactivated by protein phosphorylation. Furthermore, this
pathway can induce the transcription of certain genes. Raf,
either through downstream MEK and ERK, or independently of
MEK and ERK, can induce the phosphorylation of proteins,
which control apoptosis. Additional signal transduction path-
ways interact with the Raf/MEK/ERK pathway to positively or
negatively regulate its activity. Abnormal activation of this
pathway occurs in human cancer due to mutations at upstream
membrane receptors, Ras and B-Raf as well as genes in other
pathways (e.g., PI3K, PTEN, Akt), which serve to regulate
Raf activity. The Raf/MEK/ERK pathway also influences
chemotherapeutic drug resistance as ectopic activation of Raf
induces resistance to doxorubicin and paclitaxel in breast
cancer cells. Mutations at B-Raf have been frequently de-
tected in some malignancies including melanoma and thyroid
cancers [2]. For all the above reasons, the Raf/MEK/ERK
pathway is an important pathway to target for therapeutic
intervention. Inhibitors of Ras, Raf, and MEK and some
downstream targets have been developed and many are
currently in clinical trials. Naturally, some inhibitors are better
than others and certain “specific” inhibitors may inhibit multiple
kinases.
Fig. 1. Overview of Raf/MEK/ERK Pathway. The Raf/MEK/ERK pathway is regulated by Ras as well as various kinases, which serve to phosphorylate S/T and Y
residues on Raf. Some of these phosphorylation events serve to enhance R f activity (shown by a black P in a white circle) whereas others serve to inhibit Raf ctivity
(shown by a white P in a black circle. Moreover there are phosphatases such as PP2A, which remove phosphates on certain regulatory residues. The downstream
transcription factors regulated by this pathway are indicated in diamond shaped outlines.
1264 J.A. McCubrey et al. / Biochimica et Biophysica Acta 1773 (2007) 1263–1284
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          The p38 and JNK MAPK are a type of kinases that are mainly responsive to cellular 
stresses induced by ultraviolet irradiation, cytokines, heat shock, and osmotic shock 89,90,95.  
The four isoforms of p38 MAPK are encoded by different genes and can be phosphorylated 
by the MAPK kinase MKK6 (SKK3) 91,95. p38 MAPK seems to play a key role in apoptosis, 
differentiation, survival, proliferation, inflammation, and other stress responses 90,97. It has 
been reported that ERK1/2 can activate JNK kinases to stimulate cell proliferation 98. This is 
an example of cross-talk between members of the MAP Kinase family. The JNK pathway has 
been involved in apoptosis and survival signaling 97,98. The ERK5 cascade is activated by 
MEK 5 and also by cellular stresses 96. This pathway is one of the less studied members of the 
MAPK family. It has also been implicated in cell survival, differentiation, cell proliferation 
and anti-apoptotic signaling 97. This MAPK family responds to a large number of stimuli and 
regulate important-stimulation induced cellular processes such as cell proliferation and 
differentiation 97. As a consequence of regulating many different and even opposing cellular 
processes, any type deregulation of the MAPK signaling can play a key role in the 
development and progression of cancer 89,90. 
          Ras-Raf-MEK-ERK signaling pathway has been shown to be involved in regulation of 
gene expression 99. For instance, one study demonstrated that ERK participated in the 
regulation of HDM2 transcription via the HDM2 promoter containing binding elements for 
Ap1 and Ets 101. Both of these transcription factors are downstream substrates of the Ras-Raf-
MEK-ERK pathway. These studies also showed that HDM2 is a transcriptional target of the 
Ras-Raf-MEK-ERK signaling cascade and more important this induction of HDM2 is 
independent of p53 101. The HDM2 induced via the Ras-Raf- MEK-ERK signaling pathway 
it's functionally active to promote the degradation of p53 99. In addition to this, the activity of 
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Ras also regulates the induced effects of HDM2 on p53 since this pathway also induces the 
expression of p14 Arf  99. HDM2 activity is inhibited when it interacts with p14 Arf, protein.  
It does this by directly inhibiting HDM2 ubiquitin ligase activity 100. p14 Arf activity is also 
induced by E2f, myc and Ras suggesting a possible link to mitogenic signaling pathway, that 
induces p53 99. In normal cells, the levels of p53 are determined by a balance of the opposing 
effects of the Ras-Raf-ERK signaling pathway on the induction of HDM2 and p14 Arf. 
1.5 hnRNP Proteins: Definition and Function. 
          mRNA/Pre-mRNA transcripts are found in the nucleus bound by mRNA binding 
proteins that greatly effect a transcript’s structure and function &S&$ and are found in what is 
termed ribonucleoprotein complexes (RNPs). The protein components of these RNPs that are 
not found in stable components of other RNP complexes, (such as snRNPs) also known as 
heterogenous nuclear ribonucleoproteins (hnRNPs) &. They belong to a large and diverse 
family of RNA binding proteins. The first studies conducted on these types of proteins 
suggested that nascent RNA polymerase II (RNAPII) transcripts were packaged with six core 
hnRNP protein (A1, A2, B1, B2, C1, and C2) that resemble a beads-on-a-string conformation 
for hnRNP complexes similar to the model for the packaging of DNA by histones &.   
Approximately 20 abundant, major proteins, designated from A1 (34 kDa) to U (120 kDa) 
have been characterized to belong to this family and are considered to be core hnRNPs &S&$.  
Other minor less abundant hnRNPs proteins have also been reported that are not stably bound 
to hnRNAs during immunopurification.   
          hnRNPs have a modular structure composed of one or more RNA-binding domains 
(RBDs). The RNA recognition motif (RRMs), is being the most common RBD &. These 
domains have this highly conserved globular structure. Besides these RBDs, hnRNPs contain 
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auxiliary domains, like the glycine rich domains thought to be responsible for protein-protein, 
RNA-protein interactions and subcellular localization &. Biochemically, it has been shown that 
in addition to hnRNPs playing a role as RNA packaging proteins during RNA biogenesis, they 
also have a regulatory role by binding specific RNA sequences that then associate with other 
regulatory factors &S&$. These interactions are dependent on the RBDs and auxillary domains.  
hnRNPs also undergo numerous post-translational modifications which include 
phosphorylation, ubiquitination, sumoylation, and methylation &. These modifications have 
the ability to regulate their subcellular localization, alter their RNA binding specificity and 
interaction with other cellular factors &$. Although hnRNPs are mainly localized in the 
nucleus, several remain associated to the mRNAs as the protein is transported through the 
nuclear pores, to ribosomes. The result of this is a constant nuclear-cytoplasmic shuttling for 
some hnRNPs &. The shuttling activity of hnRNP A1 relies on the direct interaction of the M9 
sequence with two transport receptors Transportin 1 and 2 &%$@&%N. 
          hnRNPs have diverse functions with significant roles in both nuclear and cytoplasmic 
compartments. They regulate gene expression in the nucleus by acting as splicing or 
transcription factors and also in the cytoplasm by modulating mRNA stability and translation 
&. One of the best known and abundant member among the hnRNPs is the hnRNP A1.  This 
protein is a member of the hnRNP A/B subfamily &. Although the best known function of 
hnRNP A1 is the modulation of alternative splicing in human and other eukaryotes, there are 
other cellular processes that this multifunctional protein plays a key role such as mRNA 




1.5a hnRNP A1  
          heterogeneous nuclear ribonucleoprotein (hnRNP A1) protein is an RNA binding 
protein first isolated from the nucleoplasm of Hela Cells 19,20,21. Research has shown that 
hnRNP A1 play a role in DNA repair, telomere biogenesis and regulation of gene expression 
at both the transcriptional and translational level. This protein binds RNA transcripts in a 
sequence specific manner, most often at the 5’ or 3’ UTR. Therefore, hnRNP A1 can 
modulate 5’ splice site selection in concert with the splicing factor, SF2/ASF.  SF2/ASF is a 
member of the serine/arginine-rich (SR) family 22. This family plays a very important role in 
both constitutive and alternative splicing. Control of alternative splicing is central for tissue 
specific differences in gene expression, and for induction of alternate products caused by 
external or internal stimuli. In addition, to its role in splicing, hnRNP A1 binds with high 
specificity to telomeric DNA sequences in vitro. The most convincing data for the 
involvement of hnRNP A1 in telomere biogenesis comes from an study where an hnRNP A1-
deficient cell line (mouse erythroleukemic cell line CB3) was shown to contain telomeres 
which were shorter than a related normal hnRNP A1 expressing cell line (CB7). Over-
expression of hnRNP A1 in the mutant cells increased telomere length 57. We have previously 
shown that there is diminished expression and altered subcellular distribution of hnRNP A1 
protein in senescent human diploid fibroblast cells. Senescent cells have terminal cell growth 
10,70. However, the molecular mechanisms that regulate these changes have not been 
elucidated. These observations suggest that hnRNP A1 is potentially involved in regulating 




1.5b hnRNP A1 gene and protein 
          The hnRNP A1 gene is found on chromosome 12 (12q13.1).  Previous research found 
that the promoter regions of the hnRNP A1 gene contained many E boxes which bind to the c-
myc oncoprotein 37. Therefore, hnRNP A1 gene A1 may be regulated by oncogenes 37. The 
hnRNP A1 gene is able to generate multiple isoforms through mRNA alternative splicing and 
post-translational modification. hnRNP A1 protein and its splice variants make up the most 
common gene products in the hnRNP A/B family 20,21. hnRNPs were first classified as RNA 
binding proteins which bind nascent polymerase II transcripts 61. The hnRNP A1 gene is 
translated into a protein which consists of 320 amino acids 67. hnRNPA A1 protein is among 
the best characterized of the 24 hnRNP proteins identified thus far. This basic protein migrates 
in the 34 kDA range 40,41. hnRNP’s are expressed in a cell-type specific manner in vivo and 
studies have demonstrated that hnRNP’s predominate in the nucleus 49. However, hnRNP 
proteins such as A1, D, F/H also localize to the cytoplasm of several tissues 61. Different stress 
conditions, including UV light, osmotic pressure changes, and inhibition of transcription 
induce a dramatic translocation of hnRNP A1 from the nuclear to the cytoplasmic 
compartment and a concominant increase in its phosphorylation 41,42. More important, the 
subcellular localization of hnRNP A1 appears to be dependent upon the transcriptional state of 
the cell 52. Studies have shown that during active transcription in early mouse embryos, 
hnRNP A1 is localized to the nucleus 105. However, when transcription is not occurring it is 
evenly distributed between the nucleus and cytoplasm 43,105. Further, transcriptional inhibition 
of RNA polI is a strong trigger for nucleo-cytoplasmic translocation of the protein 44, thus 
suggesting that hnRNP A1 may change subcellular localization depending upon where it is 
needed in the cell. 
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1.5c hnRNP A1 protein domains 
          hnRNPs have a modular structure consisting of one or more N-terminal RNA binding 
domains and a C-terminal regulatory domain as seen in Figure 4 20,21. There are three types of 
RNA binding domains that have been identified: 1) the RBD/RRM/RNP-CS motif, which is a 
RNA-binding/RNA-recognition motif/RNP consensus motif; 2) the RGG box, and 3) the K-
homology (KH) motif 41. Structurally, hnRNP A1 protein contains two RNA binding domain 
(RBD) motifs (also known as RRM), in the N-terminus and one RGG box (Arg-Gly-Gly) 
motif RNA binding domain in the glycine rich carboxyl terminus 33. The C-terminus of 
hnRNP A1 contain the nuclear localization (NLS) and nuclear export signal (NES) sequence 
also known as M9. The M9 sequence is required for the shuttling properties of A1 45 and is 
involved in the bidirectional transport of hnRNP A1 46,47,48. Recent studies have identified the 
F-peptide next to the M9 sequence shown to mediate bidirectional transport of hnRNP A1 49.  
The RRM1 and RRM2 contain two conserved submotifs termed RNP1 and RNP.  Within the 
RNP motif there are two highly conserved consensus sequences called RNP1 and RNP2 
separated by about 30 amino acids 46,47. The RNP 1 motif has an octapeptide which is the most 
conserved segment of the RNP motif whereas the RNP 2 hexapeptide is not as conserved 49.  
The carboxyl terminus RGG box contain closely spaced Arg-Gly-Gly repeats postulated to 
mediate protein-protein interactions and also to interact with other RNA-binding domains 46. 
The hnRNP A1 motifs involved in the modulation of alternative splicing have been studied 
previously. For instance, it has been found that hnRNP A1 acts as a negative regulator of the 
activity of SF2/ASF in 5’ splice site selection 62. If the ratio of hnRNP A1 to SF2/ASF is 
increased, distal 5’ splice site selection is promoted, while, a greater concentration of 
SF2/ASF promotes proximal 5’ splice site selection 50. It was later demonstrated analysis 
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using variant recombinant proteins containing either duplicated or deleted RRM’s that both 
RRM’s are necessary for alternative splicing 41. Furthermore, the C-terminal glycine rich 
domain is also required for alternative splicing activity, stable RNA-binding and protein-
protein interactions 41,50.  
 
 
Figure 4. The major functional domains of hnRNP A1 There are two RRM motif RNA 
binding domains in the N-terminus. A naturally occurring fragment of hnRNP A1 (UP1) is 
formed from the first 196 residues. The C-terminal domain contains one auxiliary RGG box 
motif RNA binding domain, and the combined nuclear import-export signal known as M9 
(Mayeda and Krainer, 1994). 
 
1.5d Functions of hnRNP A1 
          hnRNP A1 protein has been shown to be involved in telomere biogenesis and that the 
ectopic expression of this protein promotes telomere elongation in mammalian cells 51.  
Furthermore, gel shift assays showed that both UP1 (the catalytic subunit of A1) and A1 
selectively bind single stranded telomeric repeats in vitro 51. In addition, UV crosslinking 
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experiments of RNA-protein complexes have shown that cytoplasmic A1 protein is bound to 
polyA+ (mRNA) 3.  These results suggest that A1 may be involved in RNA export 52. hnRNP 
A1 protein is also reported to be involved in the modulation of mRNA stability and turnover 3.  
For instance, AU-rich elements are regulatory elements found in 3’ untranslated region (UTR) 
of many unstable mRNA’s 45. These defined regions promote the removal of the poly-A tail, 
and destabilizes the mRNA 3,53. Furthermore, the Au-rich elements served as binding sites for 
cytoplasmic and nuclear proteins 54,55,56,57 and therefore function as cis-acting sequences in 
post-transcriptional gene expression 3. Cytoplasmic hnRNP A1 binds to these Au-rich 
elements and this interaction leads to mRNA stability in vivo. It was also been reported that 
the inhibition of RNA polymerase II with (concomitant A1 accumulation) decreases ARE-
dependent mRNA turnover of C-fos mRNA 59. Another function of hnRNP A1 is in the 
regulation of alternative splicing via its antagonistic effects of the serine-arginine (SR) 
splicing factor 2, SF2/ASF, which promotes the distal 5’, splice site selection 41.   
Crosslinking studies have shown that SF2/ASF and hnRNP A1 display competitive binding to 
pre-mRNA 62.     
1.6 The role of hnRNP A1 in constitutive and alternative splicing 
          Alternative splicing of pre-mRNAs is a process in which varied mRNA transcripts are 
generated to provide a major source of protein diversity in higher eukaryotes. Pre-mRNA 
splicing is a nuclear process that can be constitutive or alternative 50. Constitutive splicing 
involves the removal of introns and the joining of adjacent exons in the order of their 
arrangement. Consequently a single protein is produced from a single pre-mRNA in 
constitutive splicing.  In contrast, in alternative splicing the variable use of splice sites permits 
two or more mature mRNAs to be generated from the same pre-mRNA. Among the nuclear 
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complexes primarily responsible for alternative splicing are small ribonucleoproteins snRNPs 
and SR proteins 22. One of the core proteins involved in splicing is hnRNP A1 63. Splicing 
factors which play a crucial role through concentration changes or alterations of their 
expression patterns have significant impacts on mRNA alternative splicing 64 . For instance, 
the concentration of SR proteins and hnRNP A1 proteins vary considerably in different cell 
lines and this differential expression may have an effect on alternative splicing of many pre-
mRNA’s 67. Also, the HDM2 transcript is frequently subjected to alternative and aberrant 
splicing resulting in the identification of more than 40 HDM2 splice variants in both tumors 
and normal tissues 24 as shown in Figure 5. The functions of some protein products of HDM2 
splice variant transcripts differ in various tissues 24. For instance, studies have shown that a 
particular human HDM2 splice variant, HDM2 ALT-1, missing exons 4-11, binds full length 
HDM2 and sequesters it to the cytoplasm thus enhancing p53 activation 66. While other 
studies have shown that HDM2 splice variant protein products that retain the RING finger 
domain interact with full length HDM2 resulting in the inhibition of cell proliferation 65. It has 
been speculated that these HDM2 alternative splice variants could either be causative of 




Figure 5. Summary of all known HDM2 mRNA splice variants and the domains that 
they encode 
HDM2-FL refers to full-length mRNA. At least some of the splice variants, labeled with (*), 
can be translated into protein in vitro. The sequence that is omitted in most splice forms is 
highlighted in gray. The number in parentheses indicates the reference: (1) Sigalas et al., 
1996; (2) Bartel et al., 2001; (3) Bartel et al., 2002; (4) Lukas et al., 2001; (5) Tamborini et al., 
2001; (6) Kraus et al., 1999; (7) Schlott et al., 2001; (8) Hori et al., 2000; and (9) F.B., 
unpublished data. 
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Matsumoto et al., 1998) and glioblastoma cell lines (MDM2-
LN229a, -LN229b, -LN18, -G116, and -G150 in Figure 2; Kraus
et al., 1999). In breast carcinomas, previously described splice
variants and five additional shorter isoforms (MDM2-281bp, 
-219bp, -254bp, -DelE, and -DelF in Figure 2) have been detect-
ed (Lukas et al., 2001; Hori et al., 2000). Another splice variant,
MDM2-Del.G (Hori et al., 2000), which lacks the sequence
between nucleotides 182 and 1432 of the coding region of the
MDM2 mRNA, exactly corresponds to the 219 bp form
described by Lukas et al. (2001).
Screening 87 adult soft-tissue sarcomas (STS), 85 of which
expressed the complete MDM2 coding region, revealed at least
14 additional MDM2 transcripts in 55% of the cases (Bartel et
al., 2001). Of these shorter transcripts, two (MDM2-A and -B in
Figure 2) had been described previously (Sigalas et al., 1996),
whereas the others, to date, are unique to STS (e.g., MDM2-
PM2 and -EU2 in Figure 2). Six additional novel MDM2 splice
variants were identified in primary pediatric rhabdomyosarcoma
tumors and cell lines (MDM2-FB25, -26, -28, -29, -30, and -55 in
Figure 2; Bartel et al., 2002).These variants include alternative-
ly as well as aberrantly spliced forms.
Some of the aberrantly spliced MDM2 transcripts (e.g.,
MDM2-PM2, -EU2, -KB3, and -219bp) have a common splicing
pattern that is illustrated in Figure 3. Splicing occurs at cryptic
splice donor and acceptor sites in regions with high sequence
homology and which occur as many as four times in the coding
region of the MDM2 mRNA. For example, a 10-base repeat
sequence (TGGCCAGTAT in exon 5;TGCCCAGTAT of exon 12)
is involved in the splicing of the KB3 variant (a splice variant
detected in STS; Bartel et al., 2001) and the MDM2-219bp vari-
ant first described by Lukas et al. (2001). In addition to the splic-
ing at repetitive sequences, the splice variant MDM2-DS3
(Bartel et al., 2001) shows another interesting feature. This
splice form contains a novel 87 bp sequence inserted between
exons 4 and 5. Although the function is not known, this
sequence is similar to an !-exon found in the canine MDM2
mRNA (Veldhoen et al., 1999). Therefore, MDM2-DS3 repre-
sents the first identified example of an expressed human MDM2
splice variant that contains !-exon sequence.
In summary, at least 40 alternatively and aberrantly spliced
transcripts of MDM2 mRNA have been identified in tumors, but
it is currently unknown how many of these are actually
expressed as protein. Most variant transcripts lack sequence
that encodes at least part of the p53 binding domain and the
p300 binding domain. The fact that some splice variants have
been detected only in a particular tumor type suggests that they
might contribute to the transformed phenotype of these tumors,
whereas others (e.g., MDM2-B) may be associated with tumori-
genesis in general or be generated as a consequence of the
malignant phenotype.
Relationship of MDM2 expression to tumor stage and
prognosis
Results of clinical studies investigating the association between
MDM2 expression and tumor prognosis are contradictory.
Overexpression of MDM2 in acute lymphoblastic leukemia and
STS is associated with an unfavorable prognosis (Cordon-
Cardo et al., 1994; Gustafsson et al., 1998; Wurl et al., 1998). In
contrast, no relationship has been observed between MDM2
expression in glioblastomas and survival of patients (Newcomb
et al., 1998), and MDM2 gene amplification is a favorable prog-
nostic marker in non-small cell lung carcinoma and STS










1.7 The HDM2 gene and protein 
          The murine double minute 2 (MDM2) gene is a 33 KB nucleotide sequence located on 
chromosome 12 (q14.3-q15). The gene consists of twelve exons and eleven introns 60.  
Transcription of the HDM2 gene is controlled by two different promoters, referred to as P1 
and P2, which are P53-independent and P53-dependent respectively 23. The P1 promoter 
controls the basal expression of HDM2, and is positioned upstream of the first exon of the 
HDM2 gene 36. Transcription from the P2 promoter is highly regulated, responsible for 
inducible expression of HDM2, and is found in the first intron 36. Since the start site for 
translation is contained in exon 2, transcripts expressed from both the P1 and P2 promoters 
encode identical full-length HDM2 proteins as shown in Figure 6.   
          There is a cluster of GC boxes that lie further upstream and have been implicated in the 
differential expression of HDM2 due to an interesting polymorphism, SNP309 25. When this 
polymorphism is a guanine, it results in the ability of Sp1 to regulate HDM2 expression. The 
human HDM2 transcript is translated into a protein of 491 amino acids with multiple sizes 
ranging from about 50-90 kDa 26. HDM2 can be regulated positively by AKT, serine-
threonine kinase, leading to p53 repression. AKT phosphorylates HDM2, which leads to its 
nuclear entry and subsequent attenuation of p53 activity and p53 degradation 27. In contrast, 
p14Arf, a protein product from the CDNK2A locus has been shown as a negative regulator of 
HDM2. The p14Arfprotein binds to the central domain of HDM2, including the acidic region, 
leading to inhibition of the ability of HDM2 to act on p53 60. 
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Figure 6. HDM2 is transcriptionally regulated by multiple pathways (A) There are two 
promoters that function in the regulation of HDM2 expression. The P1 promoter controls 
basal expression of HDM2 and is upstream of exon. 1a. The P2 promoter is further 
downstream and uses a start site at an alternate first exon, 1b.The P2 promoter is inducible, 
and is regulated by response elements for a variety of transcription factors, including RXR, 
AP-1, the Ets family, Smad2, and Smad3, as well as p53 itself. A cluster of nGGGGC boxes 
act downstream from the Erk pathway. Three GC boxes control expression of HDM2, with 
one of these containing the site of a single-nucleotide polymorphism (SNP309) that influences 
the binding of the Sp-1 transcription factor. (B) The two transcripts from the P1 and P2 
promoters have distinct 59 untranslated regions (encoded by either exon 1a or exon 1b) and 
are different lengths. It should be noted that sequences corresponding to exon 1b are not 
present in the mature P1 transcript. Nevertheless, the start site of translation is contained in a 
shared exon 2 (Manfredi JJ, 2010). 
 
1.8 The HDM2 protein domains and interacting domains 
          The regulation of HDM2 has been shown to occur at different levels including gene 
expression 23 protein-protein interactions 27 and sub-cellular localization 60. The HDM2 
protein is a nuclear phospho-protein identified to interact with the tumor suppressor protein 
p53 and negatively regulates its function. The protein structure of HDM2 contains three major 
! ! $'!
functional domains: the N-terminus, the central region and the C-terminal region as shown in 
Figure 7. At the N-terminus is the main hydrophobic binding site for p53. The direct binding 
of HDM2 to the N-terminal end of p53 inhibits the transcriptional activation function of p53 
28,29. The central part of the protein contains the nuclear localization and export signals 33,34, 
the acidic region and a zinc finger domain. The nuclear localization and export signals allow 
HDM2 to shuttle between the nucleus and cytoplasm. The acidic domain is required for p53 
degradation 30,31. The C-terminal region contains the RING and Zinc finger domains. The 
RING finger domain is responsible for the ubiquitin ligase activity of HDM2, and also serves 
as a binding site for a closely related partner, MdmX 32.  
 
 
Figure 7. Structure of full-length human HDM2 protein and the cDNA that encodes it 
The domains of the human HDM2 protein and the binding sites of various proteins are 
indicated. ID1, ID2:growth inhibitory domains 1 and 2  (Brown et al., 1998).  NES: nuclear 
export sequences. NLS: nuclear localization sequence. NoLS: crytic nucleolar localization 
signal (Bartel et al., 2002). 
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encoded by splice variants could display an oncogenic function
that overrides the growth-inhibiting phenotype and/or the apop-
totic phenotype of full-length MDM2 protein. However, data that
suggest a completely opposite function have been described for
several murine MDM2 splice variants, as discussed below
(Dang et al., 2002).
Alternatively and aberrantly spliced variants of MDM2
In addition to mutations and chromosomal aberrations, splicing
of multiple pre-mRNAs is a mechanism by which gene expres-
sion can be regulated or altered. Splicing can occur either “alter-
natively” at intron-exon borders by using genuine donor and
acceptor splice sites, or “aberrantly” at cryptic splice sites within
introns or exons.The usage of different promoters can also gen-
erate alternative transcripts. For example, MDM2 gene tran-
scription can occur from two independent promoters.
Transcripts that arise from the constitutive P1 promoter lack
exon 2, whereas the p53-sensitive P2 promoter generates tran-
scripts lacking exon 1 (Zauberman et al., 1995; Figure 1A).
These mRNAs are identical except for the 5!-untranslated
region (Barak et al., 1994). However, transcription from P2 is
approximately 6-fold greater than that from P1 (Landers et al.,
1997). The proteins derived from these two mRNAs are identi-
cal, as translation begins in exon 3, but the translation of the
shorter P2-derived transcript is more efficient in tumor cells
(Brown et al., 1999).
The analysis of expression of the MDM2 oncogene has
revealed the presence of multiple, differ-
ent sized MDM2 transcripts and MDM2
protein isoforms in NIH3T3 cells (Haines
et al., 1994). After the determination of
the exon-intron structure of the murine
MDM2 gene (Oca Luna et al., 1996), it
was confirmed that two of these tran-
scripts were alternatively spliced.
Different MDM2 isoforms have also been
identified in B cell lymphomas isolated
from E"-Myc transgenic mice (Eischen
et al., 1999). Six of these variants have
been characterized, and five were shown
not to encode portions of the p53 binding
domain because of deletions of exons 3,
5, or 4–8 (Dang et al., 2002). The sixth
variant did not contain exon 8 and gener-
ated no protein when a retrovirus con-
taining its cDNA was used to transduce
MEFs. An alternate translation start site
at amino acid 198 was utilized by two of
the variants generating identical N-terminal truncated MDM2
proteins (Dang et al., 2002). Although none of these murine
variants were identical to any found to date in human tumors,
the murine variant V3 demonstrated the most similarity to the
splice variant MDM2-A (Figure 2). MDM2 mRNA transcripts of
3.3, 1.6, and 1.5 kb have been detected in tumors derived from
a murine mammary tumor model, the shorter transcripts having
lost a portion of the C-terminal coding region (Pinkas et al.,
1999).
In human breast carcinoma tissue, transcripts of 6.7, 4.7,
and 1.9 kb have been detected (Pinkas et al., 1999), with the
1.9 kb mRNA lacking exon 12. Western blot analysis of a panel
of human breast carcinomas demonstrated that truncated
MDM2 isoforms of 85, 76, and 57 kDa were expressed in addi-
tion to the full-length 90 kDa protein (Bueso-Ramos et al.,
1996).
A detailed analysis of the MDM2 mRNA in ovarian and blad-
der cancers revealed alternative as well as aberrant splicing
(Sigalas et al., 1996). Sigalas and coworkers have described
five MDM2 transcripts (MDM2-A, -B, -C, -D, and -E in Figure 2)
that lack sequences that encode at least part of the p53 binding
domain, the nuclear localization and export sequences, and the
acidic domain. In vitro expression studies confirmed that the
protein isoforms encoded by four of these splice variants
(MDM2-A, -B, -C, and -D in Figure 2) are unable to bind p53.
Individual or multiple splice variants have also been detected in
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1.9 HDM2 and cancer 
 
          HDM2 is a well-characterized oncogene found to be amplified 7% in of all human 
cancers 60. There is a correlation between HDM2 gene amplification and expression with an 
increased in tumorigenic potential 60. In addition to HDM2 p53 dependent oncogenic 
properties, it has been reported to have p53 independent tumorigenic functions 36. For 
instance, HDM2 has the ability to interact with the tumor suppressor pRb and inactivate its 
function. The p53 independent tumorigenic properties of HDM2 was demonstrated in 
transgenic p53 null mice 36. Transgenic mice with the entire HDM2 gene and a p53 null 
background are predisposed to spontaneous tumor formation and have a high incidence of 
lymphoma and sarcoma 38. It has been shown that SNP309 correlates with the incidence of 
tumorigenesis in certain patient populations, thereby emphasizing the role of HDM2 as an 
oncogenic modifier in human cancer  25. 
          In the experimental aims outlined in this study, we want to determine the underlying 
mechanism of how hnRNP A1 modulates HDM2 gene expression given our preliminary 
observation that the levels of HDM2 mRNA increase with the down-regulation of hnRNP A1 
and decrease with the overexpression of hnRNP A1 (Shimada, and Hubbard). The mechanism 
by which hnRNP A1 could potentially regulate HDM2 gene expression is not yet understood. 
In order to better understand how hnRNP A1 could potentially regulate HDM2 gene 
expression, we will measure the nuclear HDM2 pre-mRNA levels.  
To further gain an insight of the underlying mechanism by which hnRNP A1 reduces 
the levels of HDM2 transcript, we will determine whether hnRNP A1 has an effect on HDM2 
half-life. We hypothesized that hnRNP A1 regulates HDM2 expression by directly binding to 
HDM2 mRNA and that there may be a stage in the regulation of HDM2 mRNA in IMR-90 
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cells where the export of HDM2 mRNA is promoted by hnRNP A1 via phosphorylation by 
MNK1 and consequently affect the HDM2 gene expression. We also hypothesize that there 
also exists the possibility that hnRNP A1 could be indirectly involved in the p14Arf -p53-
HDM2 pathway. Previous studies have investigated the involvement of this pathway in 
replicative as well in premature senescence states 23. Furthermore, it has been shown in our 
lab that overexpression of hnRNP A1 in human diploid fibroblasts modulated the two mRNA 
isoforms of the INK4a locus, p14Arf and p16 Ink4A. Consequently, we assume that p14Arf tumor 
suppressor is an interesting candidate for linking hnRNP A1 indirectly to the ARF-P53-
HDM2 pathway and the concomitant up-regulation of p53, p21cip1 and HDM2 leading to 
cellular senescence.   
          The research findings of the research project are important because it can add to the 
knowledge of the regulation of HDM2 gene expression. Minor perturbations in the normal 
regulation of HDM2 protein synthesis are sufficient to induce tumor development. This is 
important because hnRNP A1 has been found to be involved in translational regulation of 
BCL-XL and XIAP, anti-apoptotic proteins. These proteins promote tumor cell survival. More 
research is needed to understand the molecular mechanisms that regulate HDM2 gene 
expression, a key regulator of p53 function in the cell with consequent implications for the 









Chapter 2 Materials and Methods 
2.1 Cells culture:  
     Experiments were performed using young IMR-90 fibroblasts. This type of cell strain was 
derived from fetal lung fibroblasts. Cells were culture at at 37oC in DMEM-HAM media 
supplemented with 10% fetal bovine serum (FBS) and 1% penicilllin/streptomycin 
(Mediatech, Gibco-Life Technologies, Manassas, VA). Cells were kept in a 37oC, 5% CO2 
incubator.  /7D"C!FC6!87I2C<7D!5F"<7!C!F77U!CAD!6VW@<V25"9C57D!C5!&XN!I78!IC66C37!
2.2 Cell lysis and protein quantification: 
 
     Protein lysates were isolated from cells that were rinsed 3 times in ice cold 1X phosphate 
buffered saline (PBS;137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4 x 7H2O, 1.4 mM 
KH2PO4,), pH 7.4, and 1 mL of cold RIPA lysis buffer (Thermo scientific Rockford, IL) in 
0.1ml of 1X Halt protease inhibitor Cocktail (Thermo scientific Rockford, IL), and 0.1mL of 
Halt Phosphatase Inhibitor Cocktail I (Thermo scientific Rockford, IL) was added to each 
100mm culture dish. Cells were scraped and lysed by incubating with lysis buffer for 30 
minutes and then passing thorough a 25 gauge needle 3 times. Lysates were collected by 
centrifugation at 12,000 rpm at 4ºC for 15 min. Supernatants were then transferred into fresh 
1.5 mL Eppendorf tubes. Protein concentration was quantified in triplicate using the RCDC 
Protein Assay (Bio-Rad, Hercules, CA) 
2.3 Subcellular fractionation: 
     Cellular fractionation for protein analysis in nuclear and cytoplasmic fractions was 
performed using subcellular protein fractionation kit for cultured cells (Thermo Scientific). 
This fractionation kit allowed the stepwise separation and preparation of cytoplasmic and 
nuclear extracts. These subcellular fractions were used to extract nuclear and cytoplasmic 
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RNA using Trizol as described below or used directly for western blot analysis of cytoplasmic 
and nuclear protein levels. 
2.4 Western blot analysis: 
     Western immuno-blotting protocols were used to isolate, estimate, separate and analyze 
proteins in IMR-90 cells. We detected the protein levels of hnRNP A1, HDM2, p14, p53, 
Actin, GAPDH, and HA from protein extracts as described above. Cell lysates were 
suspended in 4x Laemmli sample buffer (Bio-Rad, Hercules, CA) (145), separated by 4-20% 
precast polyacrylamide gel, and electrophorosed at 160 volts until the dye front reached the 
reference line. Proteins were transferred onto PVDF membranes in transfer buffer (10X Tris-
Glycine and methanol). Nonspecific binding was blocked by incubating the membranes in 
Odyssey blocking buffer and 5% nonfat dry milk at room temperature for 1 h. Membranes 
were incubated in the appropriate dilution of primary antibodies in Odyssey blocking buffer 
0.2% Tween-20 overnight at 4°C. Blots were washed four times for 15 min per wash in wash 
buffer (0.1% Tween-20 in 1X PBS) followed by incubation in IR-Dye secondary antibody  
(Li-COR) diluted in Odyssey blocking buffer (0.2% Tween-20, 0.01% SDS) for 1 h at room 
temperature. The blots were washed four times for 20 min each in wash buffer (0.1% Tween-
20 in 1X PBS).  The Odyssey system (LI-COR Biosciences) was used for antigen detection. !
Table 1.  
Primary antibodies used for Western Blot 
4B10 for hnRNP A1 Generously provided by Dr. Serafin Pinol-
Roma 
anti-"-actin (Millipore, Billerica, MA) 
anti-HDM2 Generously provided by Dr. Jill Bargonetti 
Anti-p53 Generously provided by Dr. Jill Bargonetti 
! ! M&!
SC-8340 for p14 Arf (Santa Cruz Biotechnology, Santa Cruz,CA) 
Anti-HA Tag (Millipore, Billerica, MA) 
 
Anti-Lamin (Cell Signaling Technology) 
Anti-HSP90  (Cell Signaling Technology) 
Anti-hnRNP A0 (Cell Signaling Technology) 
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2.5 Transient Transfection:  
 
                 The plasmids used for this study were nucleus-localized shuttling-deficient, hnRNP A1 
construct name LXSNP-A1 and pMT-A1(276)HA (cytoplasmic restricted plasmid) 
generously provided by Danilo Perrotti 5. The transient transfections were performed in young 
IMR-90 cells using the Lipofectamine 2000 reagent (Invitrogen), according to the 
manufacturer’s instructions. The total amount of DNA transfected was normalized with a 
carrier plasmid LXSNP-EV.   
2.6 Overexpression of hnRNP A1 by transient transfection: 
     Young IMR-90 cells were cultured in 10 cm plates. After approximately 24 h of incubation 
when the cells reached 90% confluence, the expression plasmid pEFGP (control) or pEFGP-
A1 were transfected into IMR-90 cells in DMEM/F10 media without FBS/penicillin using 
Lipofectamine 2000 (Invitrogen) and incubated at 37oC in a CO2 incubator for 6 h. We 
changed the media to DMEM with FBS and without penicillin and incubated for 48 h at 37oC.  
2.7 Inhibition of MNK1 kinase activity: 
     Young IMR-90 cells were treated with 40uM of CGP 57380 or an equal volume of DMSO 
for three days at 37°C. Lysates were collected in RIPA Lysis buffer. Stock solutions of 20 
mM CGP 57380 were prepared by adding 1ml of DMSO to CGP 57380. 
2.8 RNA isolation, and Semi-quantitative PCR: 
     Total RNA was isolated using Trizol, according to the manufacturer’s Instructions 
(Invitrogen). The extracted RNA was treated with DNAse (Ambion) to remove any 
contaminating DNA. We checked the quality of the RNA by running the total RNA in 1% 
agarose gel. The RNA concentration was analyzed by spectrophotometry and the OD 
260nm/280nm ratios were checked to ensure RNA quality. RNA was stored in sterile water at 
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-80°C. This total RNA was used for the cDNA and PCR amplification using the Access RT-
PCR system (Promega) according to the protocol’s provided in the manufacture’s manual.  
The cDNA synthesis and PCR program used for amplification was as follows: for RT one 
cycle  at 45°C for 45 min and one cycle at 94°C for 2 min followed by PCR conditions (ii) 94 
°C for 30 s, (iii) 60 °C for 1 min, (iv) 68 °C for 2 min and (v) 68 °C for 7 min, From steps 2 to 
4, the cycle was repeated 20 times for human GAPDH and p14, 22 times for hnRNP A1 and 
30 times HDM2. The primers used for these amplifications are listed in table 2.  
Table 2. 
Primers used for RT-PCR 




B-actin  F-CGTGGGCCGCCCTAGGCACCA 
R-TTGGCCTTAGGGTTCAGGGGGG 
HDM2 (Exon 2-3) F-ATTGGAGGGTAGACCTGTGG 
R-TGGTCTAACCAGGGTCTCTTG 
GAPDH  F-CCCAGCCTCAAGATCATCAGCAATG 
R-ATGGACTGTGGTCATGAGTCCTT 
Pre-HDM2  F-GCATTCCTGTGACTGAGCAG 
R-TCAGGAAGCCAATTCTCACG 
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2.8a Gene expression using real time:      
                 Real time PCR experiments on selected genes were performed using an Applied 
Biosystems 7500 real-time PCR system that utilizes SYBR green expression Assay. The 
reactions were performed according to standard methods using the universal Power SYBR 
green Master PCR mix, at a final reaction volume of 20ul. For the SYBR green expression 
assay, we used the following conditions 50°C for 2 min, 95°C for 10 min followed by 40 
cycles of 95°C for 15 seconds and 60°C for 1 min using primers listed in Table 2. mRNA 
were quantified using the formula for comparative CT method, in which the amount of target 
is normalized to an endogenous reference and relative to a calibrator is given by 2-logCT ( 
Applied Biosystems).  
2.9 Pre-hdm2 mRNA expression: 
     Young IMR-90 cells were transiently transfected with GFP-empty vector or GFP-A1 for 
48 hrs followed by incubation with DMEM containing 0.5 mM 5-ethynyluridine (5-EU) 
(Invitrogen) at 37°C for 40 min. The cells were then harvested, and newly synthesized RNA 
labeled with 5-EU was biotinylated using click chemistry and isolated through binding to 
streptavidin attached to magnetic beads using a click-iT nascent RNA capture kit (Invitrogen) 
following the protocol recommended by the manufacturer. cDNA was synthesized from the 
newly synthesized RNA and then subjected to Real time PCR using SYBR green expression 
assay. 
2.9b  Subcloning:  
     Enzyme digestion of PGEX-2T plasmid with BamHI and EcoRI restriction enzyme 
containing the cDNA insert name miniprotein 4 (MP4) coding for the HDM2 transcript 
fragment. The MP4 insert was generated by PCR and was cloned into PCR2.1 and 
subsequently substituted into the PGEX-2T plasmid. The PGEX-2T plasmid with the HDM2 
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insert was kindly provided by Dr. Meek (University of Dundee). The plasmid was digested 
with EcoRI and BamHI restriction enzymes followed by electrophoresis on 1% Agarose gel to 
confirm correct insert size which is about 1077 bp and gel purified using the Qiagen gel 
purification kit. The MP4 insert was ligated into the PCR2.1, a linearized vector supplied with 
the TA cloning Kit Dual promoter with PCR2.1 vector (Invitrogen). After ligation, construct 
was transformed into One shot TOP10 chemically competent E. coli following the protocol 
provided with the kit. We picked about 20 white colonies for plasmid isolation and restriction 
enzyme analysis to confirm MP4 insert was ligated into PCR2.1 vector. The PCR2.1 vector 
with the MP4 insert was used as a DNA template for in vitro transcription of HDM2. This 
plasmid template was first linearized with EcoRI restriction enzyme and treated with 
proteinase K and 0.5% SDS to remove any residual RNase A or other inhibitors of 
transcription introduced in the mini-prep procedures.  
2.9c In Vitro Transcription: 
     HDM2 RNA unlabeled and biotin-14-CTP labeled probes were synthesized with 
Maxiscript Kit (Invitrogen) according to manufacturer instructions. Biotin-14-CTP labeled 
and unlabeled RNA probes were produced by SP6 RNA polymerase using 1ug of linearized 
DNA template, in a 20ul mixture containing 0.5mM ATP, 0.5mM GTP, 0.5mM UTP, 0.3mM 
CTP and 0.2mM of biotin-14-CTP for labeled RNA probe or used 0.5mM CTP for unlabeled 
RNA probe. This mixture was incubated for 1h at 37°C. The reaction was treated with 
TURBO DNase provided in the kit and purified by precipitation with 5 M ammonium acetate 
and 100% ethanol. The purified transcript was quantified with Nanodrop spectrophotometer 
and subsequently used for RNA-Electrophoresis Mobility Shift Assay (REMSA). 
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2.9d RNA-Electrophoresis Mobility Shift Assay (REMSA): 
     For the binding reactions, in-vitro transcribed 2nM of biotin-labeled HDM2 RNA probe 
were reacted with 5ug of IMR-90 nuclear extract. For supershift experiments, 0.5ug of anti-
hnRNP A1 was added to 5ug of nuclear extract IMR-90 cells and incubated on ice for 30 
minutes prior to adding to the 20ul binding reaction containing (1x REMSA binding buffer, 
5% glycerol, 3.2 mM MgCl2, 25 ug of tRNA, 1 mM DTT, 75 mM KCl, 0.1 mM EDTA). 20 
uM of unlabeled HDM2 RNA probe was added as a specific competitor together with the 
biotin-labeled HDM2 RNA probe. Binding reactions were incubated for 30 min at RT. The 
RNA-protein complexes were re-suspended in 5X loading buffer and resolved by 
electrophoresis in 4-6% polyacrylamide gel in 0.5X TBE (450 mM, 450 mM boric acid, 10 
mM EDTA, pH 8.3). These RNA-protein complexes were transferred to Nylon membrane in 
0.5X TBE. Transferred RNA to crosslinked membranes by irradiating the membrane at 
120mJ/cm2 for 1 minute with UV-light crosslinker instrument (Hoefer Scientific 
Instruments). The biotin-labeled RNA was detected by Lightshift chemiluminescent RNA 
EMSA kit (Thermo-Scientific) as indicated in the protocol from the kit.  
2.9e Biotin Pull down Assay: 
     Biotinylated transcripts were obtained by reverse transcription with the Maxiscript Kit 
(Invitrogen) according to manufacturer instructions and as previously described above in 
section 3.2. The biotin pull down assay was performed by first incubating hnRNP A1 
antibody (4B10) with Dynabeads Myone streptavidin (Invitrogen) for one hour at 4 deg.  
Also, incubated Biotinlabeled HDM2 mRNA (MP4 probe) or B-actin RNA probe with 25 ug of 
IMR-90 cell lysate for one hour at RT. Following this incubation, we added the biotinylated 
RNA probes and protein lysates mixtures to the Myone streptavidin beads coated with 4B10 
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(hnRNP A1 antibody) and performed a second overnight incubation. Immediately subjected 
the protein-RNA complexes to western blot analysis as described in section 2.4 to detect 















































          Human homolog double minute 2 (hdm2), is a well characterized proto-oncoprotein that 
binds to p53 and inhibits its transcriptional activities or targets it for proteosomal degradation 
27,28,29. More important, p53 induces the expression of the HDM2 gene demonstrating that 
HDM2 and p53 form an auto-regulatory feedback loop 23. The tumor suppressor p53 performs 
cellular functions both in the nucleus and cytoplasm. In the nucleus, p53 behaves as a 
transcription factor for genes that regulate the cell cycle and apoptosis. In the cytoplasm, it 
performs pro-apoptotic factor functions independent of transcription 106. p53 is one of the most 
studied and well known stress-induced protein due to its importance in carcinogenesis, 
apoptosis and cellular senescence 25,36,38. Due to the essential regulatory role that HDM2 has 
on p53, aberrant transcriptional or post-transcriptional regulation of HDM2 expression results 
in failure to initiate apoptosis in response to DNA damage.  
          Previous studies have shown that hnRNP A1 associates with mRNA transcripts 
containing reiterated AUUUA sequences also known as AU rich elements (AREs) 107. These 
regulation elements are most often found in the 3’ UTR of mRNA responsible for 
translational repression and mRNA destabilization 107. For instance, it has been reported that 
hnRNP A1 binds to the AREs of mRNA coding for interleukin 2 (IL-2) and granulocyte-
macrophage colony-stimulating factor (GM-CSF) demonstrating that hnRNP A1 plays a role 
in the regulation of mRNA stability and translation of these proteins 3,58. We have previously 
shown that hnRNP A1 associates with HDM2 mRNA and modulates its mRNA levels. These 
findings suggest that hnRNP A1 is directly or indirectly involved in the regulation of HDM2 
gene expression. However, the involvement of hnRNP A1 in the regulation of HDM2 gene 
expression remains to be elucidated 7.   
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3.1 Results 
A. Effect of GFP-A1 overexpression on HDM2 and p53 protein levels.   
          Our preliminary findings show that hnRNP A1 interacts with HDM2 mRNA. This 
association between hnRNP A1 and HDM2 mRNA was demonstrated using a RNA co-
immunoprecipitation technique. Next, we investigated whether hnRNP A1 affected HDM2 
expression by silencing or over-expression of hnRNP A1. We found a significant change on 
the level of HDM2 mRNA by the modulation of hnRNP A1 expression (Figure 8a,b). We also 
investigated whether the protein level of HDM2 was also lowered with the overexpression of 
hnRNP A1. To determine whether hnRNP A1 modulates HDM2 and p53 protein levels, young 
IMR-90 cells were transiently transfected with GFP-A1 and GFP-Empty vector for 48hrs and 
the level of HDM2 protein was determined by western blot Analysis. We also assessed the 
levels of p53 since its levels are primarily dependent on HDM2. We found that overexpression 
of GFP-A1 resulted in slight decrease of HDM2 protein levels and a significant increased in 
p53 levels (Figure 9. lane 1 and 2). We expected lower HDM2 protein levels following the 
decrease in HDM2 mRNA levels but did not observed this suggesting that cellular protein 
levels cannot be totally predicted from mRNA measurements. For instance, studies conducted 
by various groups such as Vogel et al. pointed out that transcription, mRNA export, decay, 
translation and protein degradation are key processes in determining steady state protein 
concentration 128. For this reason, we decided to look at the regulation of HDM2 gene 
expression at the transcriptional level and also how does mRNA export and decay contribute 
to the regulation of HDM2 gene expression. First, we decided to look at the potential role of 
MNK1 as one way in which it could regulate the expression of HDM2 via hnRNP A1. 
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B. Effect of MNK1 inhibition on the expression level of HDM2 and hnRNP A1.  
          Based on previous findings where it was demonstrated that ERK was involved in the 
transcription of HDM2, Blayes et.al 101 investigated the role of Ras-Raf-MEK-ERK pathway 
in the regulation of the HDM2 expression independently of p53. The findings from this study 
showed that this signaling pathway plays a key role in the regulation of HDM2 gene 
expression by modulating the HDM2 mRNA export to the cytoplasm. It was shown that it up-
regulates the HDM2 protein levels in human breast cell lines by inducing the export of HDM2 
mRNA 101. This study reported that when the T47D cancer cells were exposed to MEK 
inhibitor, UO126, for 24 hours, it lowered HDM2 proteins levels 101. Further studies by 
Blayes et al., demonstrated that MNK1, downstream effector of the MEKs is also involved in 
the HDM2 mRNA export in breast cancer cells. The results from MNK1 inhibition were 
similar to those obtained with the MEK inhibitor, UO126 in which it resulted in the 
suppression of endogenous HDM2 mRNA export pathways and reduction of HDM2 protein 
abundance.  
          To determine whether MNK1 activity is necessary for HDM2 protein synthesis, we 
blocked the MNK1 kinase activity using the following inhibitor: 4-Amino-5-(4-fluoroanilino)-
pyrazolo[3,4-d]pyrimidine(CGP 57380). Young IMR-90 cells were treated with MNK1 
inhibitor for three days in the presence or absence of 40 uM CGP 57380. The data obtained 
from previous studies demonstrated that 40uM was the concentration needed to block the 
MNK1 kinase activity as indicated by the disappearance of the 25 kDa band in young IMR-90 
cells that corresponds to phospho-eIF4E following this treatment with MNK1 inhibitor 2. We 
detected specific protein levels with 4B10 monoclonal hnRNP A1 and anti-HDM2 antibodies. 
The results from the western blot analysis shown in Figure 9 are similar to previous results 
! ! N$!
obtained 9 following inhibition of MNK1 where the inhibitor slightly decreased the total 
HDM2 protein level compared to the DMSO treated fraction. As previously reported, the 
endogenous hnRNP A1 protein levels did not change significantly compared to DMSO treated 
cells (Figure 10). These finding suggests that MNK1 inhibition does not alter the expression 
of hnRNP A1. However, the endogenous HDM2 protein level decreased slightly with MNK1 
inhibition. Subsequently, we next investigated whether the observed partial suppression of 
HDM2 protein level with MNK1 inhibitor treatment is due to the regulation of HDM2 mRNA 
export from the nucleus to the cytoplasm as previously reported by other studies 9. 
C. Effect of MNK1 inhibition on the nuclear export of HDM2 transcript. 
          As previously mentioned it has been shown that MNK1, is involved in the export of 
HDM2 mRNA from the nucleus in normal and cancer cells 9. In this study, it was 
demonstrated that MNK1 and eIF4E (eukaryotic translation initiation factor) are the two 
downstream effectors of MEKs that promote HDM2 mRNA export 9. Furthermore, the eIF4E 
dependent export of HDM2 mRNA to the cytoplasm relies on the activity of both MEK and 
MNK1 kinases consistent with the known role of phosphorylation of eIF4E in its regulation of 
mRNA export 9. We have previously shown that p38 MAPK is required for the subcellular 
distribution of heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) in senescent IMR-90 
cells 10. Research studies conducted in our lab found that MNK1, a downstream kinase in the 
p38 MAPK pathway regulates the phosphorylation and subcellular distribution of hnRNP A1 
in senescent IMR-90 cells 2.        
          To investigate the role of MNK1 in the export of HDM2 mRNA, young IMR-90 cells 
were treated with 40uM MNK1 inhibitor or DMSO and subjected to cellular fractionation 
with Promega subcellular fractionation kit. Real time PCR was performed on total and 
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cytoplasmic extracts to determine the levels of HDM2 mRNA transcripts. The results from the 
real time PCR experiment in Figure 11 are consistent with previously reported results 9 for 
CGP57380 (MNK1 inhibitor). We observe an overall decrease in expression of HDM2 
transcript in total cellular RNA probably due to inhibition of transcription through an 
unidentified mechanism. We also observed a greater decrease in cytoplasmic HDM2 mRNA 
in comparison to the DMSO-treated fraction suggesting that HDM2 mRNA export could be 
inhibited as previously reported 9. 
D. Effect of Actinomycin D on subcellular localization of hnRNP A1 and HDM2 protein  
 
levels 
             hnRNP A1 is mainly found in the nucleus, however, it has been reported that stressful 
stimuli such UVC irradiation and osmotic shock can induce cytoplasmic accumulation of 
hnRNP A1. In addition to this, previous studies by Pinol-Roma et al. found that actinomycin 
induced the cytoplasmic accumulation of hnRNP A1 in Hela cells 6. Actinomycin D is a 
transcriptional inhibitor that inhibits cell proliferation by forming a stable complex with single 
stranded DNA and blocks the movement of RNA polymerase that interferes with DNA-
dependent RNA synthesis. It has been also shown that this inhibition of transcription not only 
does it allow continue shuttling of hnRNP A1 but it also accelerates its export 108. We used 
actinomycin D (5ug ml-1) to induce the cytoplasmic accumulation of hnRNP A1 in young 
IMR-90 cells. The treatment with actinomycin D resulted in the cytoplasmic accumulation of 
hnRNP A1 as shown in Figure 12. These results confirmed previous findings in which 
treatment of Hela cells with actinomycin D also resulted in the cytoplasmic localization of 
hnRNP A1. We hypothesized that the treatment of young IMR-90 cells with actinomycin D 
should lower HDM2 protein levels because of the accumulation of hnRNP A1 in the 
cytoplasm. The western blot results from Figure 13b showed that the decrease in HDM2 
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protein levels correlate with the cytoplasmic accumulation of hnRNP A1 during the 
actinomycin D treatment. Although these results suggest that cytoplasmic hnRNP A1 could be 
reducing the translation of HDM2, further studies are needed to confirm this finding. 
E. Effect of a nucleus-localized, shuttling-deficient hnRNP A1 on HDM2 mRNA and 
protein expression. 
          We have evidence that hnRNP A1 participates in the regulation of mRNA 
nucleocytoplasmic trafficking. A number of studies have shown that hnRNP A1 is a regulator 
of mRNA nuclear export 3. The NC shuttling activity of hnRNP A1 depends on the integrity 
of a 38 A.A sequence, the M9 domain, which provides the signal for hnRNP A1 nuclear 
import and export 4. NLS-A1 –HA is expected to retain the A1 nuclear localization (and 
perhaps nuclear function while lacking nuclear export activity 5. The NLS-A1-HA construct 
contains the bipartite-basic type NLS of hnRNP K fused in frame with the N terminus of an 
HA-tagged A2 mutant (A1-G274A-HA) which lacked both nuclear import and export 
activities and inhibits A1-dependent mRNA export 5. Previous studies have shown that this 
mutant construct inhibits hnRNP A1 dependent mRNA export when microinjected into the 
nuclei of Xenopus oocytes 45. Additional studies in hematopoietic cells demonstrated that this 
dominant negative impaired the endogenous hnRNP A1 nuclear to cytoplasmic shuttling 
activity and thus inhibited A1-mediated nuclear export of mRNAs 5. These findings suggest 
that the dominant negative construct displaces endogenous hnRNP A1 for nuclear factors 
required for hnRNP A1 mRNA nuclear export 5.  
          We hypothesized that expression of NLS-A1-HA would interfere with the 
nucleocytoplasmic shuttling activity of wild type hnRNP A1 as previously demonstrated 5. To 
investigate the effect of NLS-A1-HA expression on mRNA and protein levels of HDM2, we 
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performed transient transfection of NLS-A1-HA and LXSP (empty vector) in young IMR-90 
cells. The semi-quantitative PCR analysis of the nuclear and cytoplasmic transcript levels 
between the control (EV) and NLS-A1-HA cells revealed a significant decrease in 
cytoplasmic HDM2 mRNA in NLS-A1-HA transfected cells as shown in Figure 14. This 
result suggests that the NLS-A1-HA alters the hnRNP A1-regulated HDM2 mRNA trafficking 
in IMR-90 cells. The hnRNP A1 mRNA would be expected to shuttle into the cytoplasm even 
in the presence of the NLS-A1-HA dominant negative as shown by others 5 which is 
consistent with the results in Figure 14. To examine whether the decrease in HDM2 protein 
levels seen during actinomycin D treatment depends on hnRNP A1 shuttling activity, we 
performed transient transfection of NLS-A1 and LXSP (empty vector) in young IMR-90 cells.  
Following transfection, protein extracts were collected and HDM2 protein levels were 
assessed by Western blot analysis. HDM2 protein levels increase and while p53 and p21 
levels decreased in lysates transiently transfected with NLS-A1 (Figure 15). The HDM2 
protein levels do not decrease as expected following the decrease of HDM2 mRNA levels 
after NLS-A1 transfection. These findings suggest that the shuttling of hnRNP A1 from the 
nucleus to the cytoplasm is not affecting the HDM2 protein expression. 
          Previous research studies have shown that cytoplasmic restricted hnRNP A1 negative 
regulates the expression of endogenous XIAP levels 8. Since we find that overexpression of 
hnRNP A1 decreases HDM2 mRNA expression, we asked whether cytoplasmic localized 
hnRNP A1 could negatively regulates the expression of HDM2. To answer this question, we 
transfected IMR-90 cells with a plasmid expressing a mutant (A1-G274A-HA) hnRNP A1 
construct which lacked both import and export activities and LSXP-Empty vector 5. Forty 
eight hours after transfection, protein extracts were prepared to determine the HDM2 protein 
! ! N'!
level in LSXP-EV and A1-G274A-HA transfected cells. Western blot analysis revealed that 
overexpression of this A1 mutant reduced the endogenous HDM2 protein level (Figure 16, 
compare lane 1 and 2). These data suggest that cytoplasmic localized hnRNP A1 could be 
reducing the endogenous HDM2 protein levels by an unknown mechanism. Therefore, our 
next question would be to find whether hnRNP A1 represses the expression of HDM2 by 
binding to its 3’ UTR and whether this influences its mRNA stability and translation.  
F. Determine the effect of hnRNP A1 overexpression on the half-life of HDM2 transcript 
          We next asked whether hnRNP A1 regulates HDM2 mRNA stability. Specifically, we 
wanted to find whether the reduction of HDM2 mRNA levels observed with overexpression of 
hnRNP A1 is due to changes in HDM2 mRNA stability. One possible mechanism as to how 
hnRNP A1 is regulating HDM2 gene expression is through the destabilization of HDM2 
transcript as shown in other studies 11. For this, we performed experiments to determine 
whether hnRNP A1 has an effect on the half-life of HDM2 transcript. IMR-90 cells were 
uninduced or induced to express hnRNP A1 for 48 hrs and then treated with actinomycin D 
for various times to inhibit de-novo RNA synthesis. The level of HDM2 transcript was 
determined by Real time PCR normalized to an internal control, GAPDH. HDM2 mRNA 
levels were subsequently determined after transient transfections with GFP–A1 and GFP-EV 
for 48 hrs and incubation with 5ug/ml actinomycin D. Extraction of total RNA was done at 
the times shown in Figure 17. The relative levels of HDM2 transcript were normalized with 
the levels of GAPDH transcript and plotted as a function of time to calculate the relative half-
life of HDM2 mRNA. We predicted that the overexpression of GFP-A1 and treatment with 
actinomycin D would decrease the half-life of HDM2 transcript based on previous results 
where the half-life of HDM2 mRNA decreased with overexpression of RNPC1, an RNA 
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binding protein 11. However, we found that the half-life of HDM2 mRNA increased slightly 
from 1.0 hr as seen in control cells to 1.5 hr in GFP-A1 transiently transfected cells as shown 
in Figure 17. These results are not consistent with our original hypothesis suggesting that 
hnRNP A1 is stabilizing the HDM2 mRNA message but it could also be that hnRNP A1 is 
competing with other factors in influencing the stability of HDM2 mRNA.  
G. Effect of GFP-A1 overexpression on HDM2 pre-mRNA level 
          Given that hnRNPs associate with nascent transcripts to regulate it’s processing such as 
transcription and splicing, we next sought to determine whether the levels of HDM2 pre-
mRNA is affected by the overexpression of hnRNP A1. We measured the level of precursor 
HDM2 mRNA using the Click-iT® Nascent RNA Capture Kit (Invitrogen), to determine 
whether its concentrations are altered after overexpression of hnRNP A1. To this end, IMR-90 
cells were transiently transfected with empty vector or GFP-A1 for 48 hrs followed by 
incubation with DMEM containing 0.5 mM 5-ethynyluridine (5-EU) (Invitrogen) at 37°C for 
40 min. This kit allows us to separate newly transcribed RNA from pre-existing RNA.  
Ethynyl uridine (EU), which contains an alkyne group, is fed to cells. One unique advantage 
of Click-iT EU is that it is incorporated with high efficiency into RNA without any apparent 
effect on the global transcriptone. Once the EU is incorporated, tRNA is isolated and a biotin 
azide is clicked on to the newly synthesized pool of EU-modified RNA. The biotinylated 
nascent RNA is then captured using streptavidin magnetic beads. cDNA was synthesized from 
the newly synthesized RNA followed by subjection to qRT-PCR. As shown in Figure 18, 
lower concentrations of HDM2 pre-mRNA was observed in cells transfected with GFP-A1.  
The concentrations of GAPDH mRNA in the three conditions tested were similar (untreated, 
GFP-EV and GFP-A1 transiently transfected cells). The lower levels of pre-HDM2 mRNA 
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observed in cells that were transiently transfected with GFP-A1 suggests that hnRNP A1 
could be indirectly or directly suppressing the transcription of HDM2. Howerver, further 
studies are needed to determine if hnRNP A1 is a transcriptional repressor of HDM2. 
H. Effect of GFP-A1 overexpression on p14 mRNA and protein levels.  
 
          Previous work by Zhu et al. 70 showed that 4"3478!7:I8766"=A!279726!=;!4A*1B!0&!9"C!
=978@7:I8766"=A!<CA!64";5!547!7:I8766"=A!IC5578A!5=FC8D6!547!I&N0*K!E*10!"6=;=8E. p14 
ARF, a protein product from the CDNK2A locus has been shown to be a negative regulator of 
HDM2  27.  The p14 ARF protein binds to the central domain of HDM2, including the acidic 
region, leading to inhibition of the ability of HDM2 to act on p53 112. The ability of p14 ARF 
to arrest cells in the G1 and G2/M phases of the cycle suggested that the effects might be 
mediated via p53 38. In addition, it has been published that caveolin-1, a novel HDM2 binding 
protein, sequesters HDM2 away from p53 after oxidative stress in human fibroblasts leading 
to the stabilization of p53 and increase of p21 Cip1/WAF1 protein levels 110. Thus by sequestering 
HDM2 away from p53, caveolin-1 seems to stabilize p53 after oxidative stress. Therefore, we 
measured both the transcript and protein level of HDM2 after the induction of p14 ARF via 
hnRNP A1 overexpression. We observed that both the transcript and HDM2 protein level 
decreased and p14 mRNA and protein level increased as shown in Figure 19. These results are 
consistent with previously published results in which elevated levels of p14 ARF lead to an 
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Figure 8A. Analysis of HDM2 mRNA level after hnRNP A1 overexpression and siRNA 
transfection against hnRNP A 1. GFP-Empty (Control) or GFP-hnRNP A1 were transfected 
into IMR-90 fibroblast cells. After 2 days of incubation, total RNA was extracted from cells 
and Real-Time PCR (A) was performed with primers for constitutive HDM2 mRNA (exon 1-
3) and p53-inducible HDM2 mRNA (exon 2-3). The relative mRNA levels was quantify by 
image density analysis software (Image J) and the data represented as mean value ± SEM 
(n=3, and * p < 0.05 value). 
(B) Scrambled siRNA (Control) or siA1 were transfected into IMR-90 fibroblast cells. After 3 
days of incubation, total RNA was extracted from cells and Real-Time PCR was performed 
with primers for constitutive HDM2 mRNA (exon 1-3) and p53-inducible HDM2 mRNA  
(exon 2-3). The relative mRNA levels was quantify by image density analysis software 




























Figure 9. Effect of overexpression of GFP-hnRNP A1 on endogenous hnRNP A1 and 
HDM2 protein levels A. IMR-90 cells were transiently transfected with GFP-hnRNP A1 and 
Empty Vector for 48 hours. Whole cell lysates were prepared using RIPA lysis buffer.  30 ug 
of protein lysates were simultaneously subjected to 12% SDS-PAGE and immunoblotted for 
hnRNP A1, HDM2, p53 and actin. The membranes were stripped and reprobed for total actin 
levels. B. The relative protein levels was quantify by image density analysis software (Image 
J) and the data represented as mean value ± SEM (n=3, and * p < 0.05 value). 
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Figure 10. Effect of MNK1 inhibition on HDM2 and hnRNP A1 protein levels.   
A. Young IMR-90 cells were treated with 40uM concentration of CGP 57380 or DMSO for 3 
days. 30 ug of cell lysates were subjected to 12% SDS-PAGE and probed with the 4B10 
(hnRNP A1 antibody), anti-HDM2, and anti-actin. The membranes were stripped and 
reprobed for total actin levels. B. The relative protein levels was quantify by image density 



































Figure 11. Effect of MNK1 inhibitor on HDM2 mRNA expression. 
IMR-90 cells were treated with 40 uM CGP57380 (MNK1 inhibitor) and an equal amount of 
DMSO for 3 days. Using trizol, total RNA was isolated from total and cytoplasmic extract 

























   Figure 12. Effect of Actinomycin D on endogenous A1 protein localization. 
IMR-90 cells were treated with 5ug ml-1 of actinomycin D for 3 hours. Nucleoprotein was 
separated from cytoplasmic protein extracts. 10 ug of protein lystate were subjected to 12% 
SDS-PAGE and probed with the 4B10 (hnRNP A1 antibody), anti- lamin (nuclear marker), 
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Figure 13. Effect of Actinomycin D on HDM2 mRNA and protein levels. 
IMR-90 cells were treated with 5ug ml-1 of actinomycin D for 3 hours. A. Total RNA was 
extracted from cells and Semi-quantitative PCR was performed with primers for p53- 
inducible HDM2 mRNA (exon 2-3). B. Total, nucleoprotein was separated from cytoplasmic 
protein and 20 ug of lysates were simultaneously subjected to 12% SDS-PAGE and 
immunoblotted for  hnRNP A1, HDM2, lamin (nuclear marker), HSP90 (cytoplasmic marker) 
and actin (loading control). The membranes were stripped and reprobed for total actin levels.  
C. The relative protein levels was quantify by image density analysis software (Image J) and 






























Figure 14. Effect of NLS-A1 on levels of  hnRNP A1 and HDM2 mRNA 
IMR-90 cells were transiently transfected with NLS-A1 mutant and empty Vector for 48 
hours. Following transfection, performed cytoplasmic and nuclear RNA isolation from these 
transiently transfected IMR-90 cells and subsequently semi-quantitative PCR with a set of 
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Figure 15. Effect of NLS-A1 on endogenous hnRNP A1 and HDM2 protein levels 
IMR-90 cells were transiently transfected with HA-empty vector and HA-NLS-A1 mutant for 
48 hours. Following transfection, whole cell lysates were prepared using RIPA lysis buffer. 20 
ug of lysates were simultaneously subjected to 12% SDS-PAGE and immunoblotted to detect 
HA-empty vector, hnRNP A1, HDM2, P53, p21 and actin. The membranes were stripped and 
reprobed for total actin levels. B. The relative protein levels was quantify by image density 





































Figure 16. Effect of overexpression of A1-G274A-HA (cytoplasmic hnRNP A1 construct) 
on endogenous HDM2 protein levels. A. IMR-90 cells were transiently transfected with HA-
empty vector and A1-G274A-HA for 48 hours. 30 ug of lysates were simultaneously 
subjected to 12% SDS-PAGE and immunoblotted for HA-empty vector, hnRNP A1, HDM2, 
and actin. The membranes were stripped and reprobed for total actin levels B. The relative 
protein levels was quantify by image density analysis software (Image J) and the data 
represented as mean value ± SEM (n=3, and * p < 0.05 value). 
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Figure 17. Effect of overexpression of hnRNP A1 on the half-life of HDM2 transcript. A. 
Young IMR-90 cells were transiently transfected with empty vector or GFP-A1 for 48 hrs 
followed by treatment with 5ug/ml actinomycin D for various times. Total RNA was isolated 
and then subjected to quantitative RT-PCR analysis. The relative levels of HDM2 transcript 
were normalized with the levels of GAPDH transcript and plotted as function of time to 
calculate the relative half-life of HDM2 mRNA. B. RT-PCR products from were run on 1% 














































Figure 18. Levels of newly synthesized HDM2 transcripts following overexpression of 
GFP-A1. A. Young IMR-90 cells were transiently transfected with empty vector or GFP-A1 
for 48 hrs followed by incubation with DMEM containing 0.5 mM 5-ethynyluridine (5-EU) 
(Invitrogen) at 37°C for 40 min. The cells were then harvested, and the RNA newly labeled 
with 5-EU was biotinylated using click chemistry and isolated by binding to streptavidin 
attached to magnetic beads using a click-iT nascent RNA capture kit (Invitrogen) following 
the protocol recommended by the manufacturer. cDNA was synthesized from the newly 
synthesized RNA followed by quantification by qRT-PCR. B. RT-PCR products were run on 
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Figure 19. Effect of GFP-A1 overexpression on p14 mRNA and protein levels. A. IMR-90 
cells were transiently transfected with empty vector or GFP-A1 for 48 hours. Using trizol, 
performed RNA isolation and subsequently semi-quantitative PCR with a set of primers to 
detect HDM2, hnRNP A1, p14 and GAPDH mRNA. B. IMR-90 cells were transiently 
transfected with GFP-hnRNP A1 and empty vector for 48 hours. Whole cell lysates were 
prepared using RIPA lysis buffer. 30 ug of cell lysates were subjected to 12% SDS-PAGE and 
probed with the anti-p14 ARF and anti-GAPDH. The membranes were stripped and reprobed 
for total GAPDH levels C. The relative mRNA levels was quantify by image density analysis 






























Figure 20. Model for the role of hnRNP A1 in the gene expression regulation of HDM2. 
A. In this model, we proposed that there may be a stage in the regulation of HDM2 gene 
expression where hnRNP A1 could directly bind to HDM2 DNA and induce transcriptional 
repression of HDM2 resulting in lower levels of HDM2 mRNA. B. hnRNP A1 could be 
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Discussion and Summary 
 
          Post-transcriptional regulation of gene expression is important for the control of cellular 
processes such as cell proliferation, differentiation, development and apoptosis 115. RNA 
binding proteins are the main regulators of post-transcriptional regulation 76. hnRNP A1 is a 
multifunctional RNA binding protein implicated in the regulation of major steps in post-
transcriptional regulation of gene expression 1,76. Upon observation that hnRNP A1 binds to 
HDM2 mRNA, we sought to determine whether the modulation of the expression of hnRNP 
A1 had an effect on steady state HDM2 mRNA levels. Gene expression studies involving the 
overexpression of GFP-hnRNP A1 allowed us to investigate the underlying mechanism of 
how hnRNP A1 modulates the HDM2 mRNA levels. Given that our previous results 
demonstrated that overexpression of hnRNP A1 significantly decreased HDM2 mRNA levels, 
we next asked whether the HDM2 protein levels also decrease upon overexpression of hnRNP 
A1. Our western blot analysis data revealed that overexpression of GFP-A1 slightly decreased 
the HDM2 protein levels (Figure 9). We also observed that p53 levels increased upon GFP-A1 
overexpression suggesting that the presence of p53 could potentially up-regulate the 
expression of HDM2 (Figure 9). Previous studies have demonstrated that HDM2 can be 
transcriptionally activated by p53 forming this regulatory feedback loop with HDM2 23. Our 
results are consistent with these finding by showing that the HDM2 is a transcriptional target 
of p53 resulting in the induction of HDM2 gene expression levels.   
          In this study, we attempted to examine the role of hnRNP A1 in the regulatory 
mechanisms of HDM2 gene expression. hnRNP A1 is mainly found in the nucleus but it also 
shuttles continuously between the nucleus and cytoplasm in response to specific signals.  To 
this end, we first examined the effects of actinomycin D on the subcellular distribution of 
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hnRNP A1 and its effects of HDM2 mRNA levels. We treated young IMR-90 cells with or 
without 5ug/ml actinomycin D for 3 hours. These IMR-90 cells treated with actinomycin D 
were subcellularly fractionated into nuclear and cytosolic fractions. We found that hnRNP A1 
localized to the cytoplasm in the presence of actinomycin D as shown in Figure 12. This result 
also confirms previous findings conducted by Dr. Pinol-Roma in which it was demonstrated 
that treatment of Hela cells with actinomycin D resulted in cytoplasmic accumulation of 
hnRNP A1. Previous research studies have found that genes such as CYP2A6 could be 
stabilized in response to inhibition of RNA Pol II-dependent transcription 126. It was also 
reported in these studies that although the levels of this mRNA decreased with time in non-
treated cells, the treatment with 4uM of actinomycin D stabilized its concentration in human 
primary hepatocytes 126. Using semi-quantitative RT-PCR, we measure the levels of HDM2 
mRNA in control and actinomycin D treated cells and found that the levels of HDM2 mRNA 
were not affected by treatment with 5ug/ml actinomycin (Figure 13a). Our results indicate that 
HDM2 mRNA stability is not affected by actinomycin treatment. Next we decided to 
determine whether hnRNP A1 influences the HDM2 mRNA stability as previously described 
in Chapter 3. When we assessed the half-life of HDM2 mRNA, we found that overexpression 
of hnRNP A1 increased the half-life of HDM2 transcript suggesting that hnRNP A1 could be 
influencing the HDM2 mRNA stability.  
          We have previously shown that both MNK1 and p38 MAPK are both involved in the 
cytoplasmic accumulation of hnRNP A1 in IMR-90 senescent cells 2,10. Therefore, we decided 
to investigate how MNK1 and hnRNP A1 are linked in the regulation of HDM2 gene 
expression in IMR-90 cells. Previous studies have shown that the Ras-Raf-ERK-MEK 
signaling pathway plays a key role in the regulation of HDM2 mRNA export to the cytoplasm. 
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Furthermore, it was also demonstrated that MNK1, a downstream effector of the MEK 
signaling pathway, regulates the HMD2 mRNA export and protein levels. We found that 
IMR-90 cells treated with MNK1 inhibitor significantly reduced the HDM2 transcript in the 
cytoplasmic fraction in comparison to the cytoplasmic extract treated with DMSO. However, 
inhibition of MEK signaling pathway with MNK1 inhibitor resulted in the reduction of 
phospho-eF4E but not a significant decreased in HDM2 protein levels (Figure 10). These 
results are no consistent with previous findings where it was demonstrated that MNK1 activity 
was required for HDM2 protein synthesis in cancer cells 9. Our results suggest that HDM2 is 
only partially regulated by MNK1.   
          The regulation of the nuclear export of mRNA is of key importance for the control of 
expression of a number of cellular proteins 101. Furthermore, all nuclear mRNA exists in 
relatively large complexes with proteins and it is these complexes which interact with 
components of the nuclear export pathways that are responsible for the transporting the 
mRNA from the site of transcription to the cytoplasm 101. In chapter 3, we found that  MNK1 
inhibition results in a reduction of HDM2 mRNA in the cytoplasmic compartment compared 
to their levels in total mRNA (Figure 11). As a result of these findings, we decided to conduct 
further experiments to provide support of the hypothesis that hnRNP A1 somehow regulates 
the HDM2 gene expression at the level of nuclear export of its mRNA.   
          In order to address this question, we conducted experiments with the shuttling deficient 
NLS-A1-HA mutant to prevent the shuttling of hnRNP A1. This results in retention of hnRNP 
A1 in the nucleus. The expression of the NLS-A1-HA mutant in IMR-90 cells resulted in the 
down-regulation of the cytosolic HDM2 mRNA as shown in figure 14. These results are 
consistent with the role of hnRNP A1 in BCR-ABL leukemogenesis where the expression of 
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this dominant negative mutant was associated with a decreased in cytosolic BcL-XL, an 
apoptosis suppressor 5. The reduction of HDM2 mRNA by NLS-A1-HA could be a direct 
effect on reduced export of HDM2 mRNA or it could the result of other contributing factors 
that regulate the transcription of HDM2.  !
The total amount of mRNA is determined by the rate of gene transcription and 
degradation of mRNA 81. Regulation of RNA transcription and degradation is of key 
importance in the control of transcript levels 81. Therefore, it is crucial to include the analysis 
of rate of nuclear transcription in studies of gene expression. Nuclear run on assays provide 
the means to analyze the rate of nuclear transcription. In nuclear runs, nuclei are isolated and 
incubated with 32P-UTP analog to label newly synthesized transcripts and elongated RNA. To 
determine the effect of overexpression of hnRNP A1 on transcription of HDM2, we measured 
changes of newly synthesized HDM2 RNA with the Click –iT RNA capture kit.  This kit does 
not require the use of hazardous radioactive nucleoside analogs used in nuclear run on 
experiments. We found a down regulation of newly synthesized HDM2 pre-mRNA in IMR-90 
cells that were transiently transfected with GFP-A1 in comparison to cells transfected with 
GFP-EV suggesting that hnRNP A1 could be repressing the transcription of HDM2 (Figure 
18). Previous reports have shown that hnRNP A1 induces the transcriptional repression of 
certain genes such as thymidine kinase, y-fibrinogen and vitamin D receptor 1. hnRNP A1 
participate in these transcriptional events by associating with promoter sequences. Although 
our results suggests that hnRNP A1 potentially influences the repression of HDM2 
transcription, we need to examine first whether or not hnRNP A1 associates with HDM2 P2 
or P1 promoter by performing chromatin immunoprecipitation (Chip) assay in IMR-90 cells. 
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     Recent studies have demonstrated that overexpression of hnRNP A1 led to a reduction of 
HDM2-FL transcript levels in HaCat cells 118. More important, it was also shown that UVB 
irradiation increased the binding of hnRNP A1 to HDM2 pre-mRNA 118. The findings from 
this study are consistent with our findings where we also found that overexpression of hnRNP 
A1 decreased HDM2 transcript levels. There is also the possibility that hnRNP A1 could be 
indirectly involved in the regulation of HDM2 via p14 ARF. We found that overexpression of 
hnRNP A1 increased p14 ARF mRNA and protein levels and decreased both HDM2 mRNA 
and protein levels suggesting that p14 ARF could be down-regulating HDM2 (Figure 19).  
However, the underlying mechanism needs to be further elucidated. In summary, our data 
suggests a model wherein hnRNP A1 plays a role in the regulation of HDM2 gene expression 
at multiple levels (Figure 20). Two distinct points of regulation described previously as 
follows. First, overexpression of hnRNP A1 induces the reduction of HDM2 pre-mRNA by an 
unknown mechanism. One potential mechanism is through the interaction of hnRNP A1 with 
promoters of HDM2 DNA leading to its transcriptional repression. This reduction of HDM2 
transcription in turn lowers HDM2 mRNA levels and partially decreases HDM2 protein 
levels.  As previously mentioned, the main function of p14 ARF is to bind and inhibit HDM2 
38,70. This in turn activates the activity of p53. The second point of regulation of HDM2 gene 
expression by hnRNP A1 could be via an in-direct effect of hnRNP A1 on HDM2. We 
proposed that relative high levels of hnRNP A1 after GFP-A1 overexpression could lead to an 
increase in both p14 mRNA and protein levels. The consequent increase in p14 ARF levels 
results in lower levels of both HDM2 mRNA and protein levels (Figure 19 and 20). This 
potential regulation of HDM2 gene expression by hnRNP A1 could aid the establishment of a 
! ! P$!
dynamic equilibrium between p53 and HDM2 proteins in IMR-90 cells. This is important 













































Many reports have established the importance of hnRNP A1 as a modulator of 
alternative splicing. As previously mentioned, hnRNP A1 participates in the regulation of 
post-transcriptional regulation by binding to RNA sequences 1. Sequences that are protein 
non-coding mRNA regions are also known as un-translated regions (UTRs) have been 
demonstrated to be regulatory elements in the control of gene expression. The direct 
interaction of hnRNP A1 with these RNA sequences show that it exerts a specific regulatory 
function on genes with important functions in health and disease 1,121. For instance, it has been 
shown that hnRNP A1 interacts with the 3’ UTR of Eukaryotic translation termination factor 
3 (ERF3) mRNA 121. This specific 3’UTR contains a conserved putative hRNPA1 consensus 
binding sequence (UAGGGA) 121.   
We have previously found that hnRNP A1 is significantly down-regulated and showed 
increased cytoplasmic accumulation in senescent human diploid fibroblast cells 70,113. As a 
result of these findings, we were interested to find identify novel targets of hnRNP A1 to 
explore its role in the modulation of gene expression during cellular senescence. We were able 
to identified HDM2 mRNA as an in vivo RNA target bound in hnRNP A1 complexes isolated 
from human fibroblasts. These RNP complexes were isolated by a brief co-
immunoprecipitation step with the 4B10 hnRNP A1 specific monoclonal antibody 114. RNA 
species were identified in these complexes by reverse transcription of the RNA obtained 
followed by amplification. The products were cloned and sequenced. The gene identified was 
confirmed to belong to the Homo sapiens HDM2 gene (AF144029). However, we have not 
determined whether hnRNP A1 is directly binding to HDM2 mRNA. For these studies, we 
decided to determine if hnRNP A1 interacts directly with HDM2 transcript using RNA 
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electrophoretic mobility shift assay by incubating biotin labeled HDM2 probes covering 
different regions of HDM2 mRNA and IMR-90 nuclear extract as the source of hnRNP A1 
protein.  
" In this study, we provide evidence that a complex is formed between HDM2 RNA 
probe and nuclear protein extract from young IMR-90 cells. Furthermore, we show that 
hnRNP A1 is the RNA binding protein responsible for this complex formation. The result 
from these RNA-protein interactions studies suggests that hnRNP A1 could potentially affect 


















A. Detection of an RNA-protein complex between HDM2 mRNA and nuclear protein 
extract from IMR-90 cells.   
 Using RNA co-immunoprecipitation technique, we found that HDM2 mRNA was one 
of the putative transcripts that were bound in hnRNP A1-RNP complexes. The region of the 
mRNA that was specifically precipitated with hnRNP A1 contained two putative hnRNP A1 
consensus-binding sites 108. Figure 21 shows a schematic illustration of the HDM2 mRNA, 
which depicts the putative hnRNP A1 binding site between exon 9 and intron 10 (Ghandi, S 
and Hubbard, K).!The known consensus sequence of the putative hnRNP A1 binding site is 
UAG (G/A) 111. The result from this experiment shows that HDM2 mRNA is a novel target of 
hnRNP A1.  
To order to validate that hnRNP A1 interacts and forms a complex with HDM2 
mRNA, we performed RNA electrophoretic mobility shift assay (REMSA). The REMSA 
method consists of visualizing the RNA-protein complexes by comparing the migration of 
RNA in the presence of a protein 124. It also involves the analysis of a specific RNA sequence 
(RNA probe) with the protein of interest 124. We synthesized HDM2 RNA probes from cDNA 
inserts ligated to GEX-2T plasmid generously obtained from Dr. David W. Meek (University 
of Dundee). As previously mentioned these GEX-2T plasmids comprised overlapping regions 
of HDM2 referred to as “mini-proteins” termed MP1-MP4; see Figure 24 A. First, we cut the 
inserts with BamHI and EcoRI restriction enzymes (Figure 22) and purified it with Qiagen gel 
purification kit. Subsequently, we were only able to ligate the MP4 insert into PCR2.1, a 
linearized vector supplied with the TA cloning Kit Dual promoter and PCR2.1 vector 
(Invitrogen). Transformation of this construct into the One shot competent E. coli cells 
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(Invitrogen) was performed according to Material and Methods. We performed plasmid 
isolation using Qiagen kit. Restriction enzyme analysis confirmed that MP4 insert was 
successfully ligated into the PCR2.1 vector. The insert was subsequently released following 
digestion with EcoRI and BamHI restriction enzymes as shown in Figure 22. The PCR2.1 
vector with the MP4 insert was used as DNA template for in vitro transcription of HDM2 
RNA probe (MP4 probe). We labeled the HDM2 RNA probe with biotin-14-CTP resulting in 
Biotinlabeled HDM2 mRNA (MP4 probe) as described in Material and methods. We performed 
RNA EMSA by incubating the HDM2 mRNA (MP4 probe) spanning part of exon 11, Exon 
12 and the entire HDM2 3’UTR (Figure 24 a) with the IMR-90 cell nuclear protein extract.  
We found that an RNA-protein complex (HDM2 complex) was readily detected in young 
IMR-90 cells nuclear extract (Figure 23). Furthermore, we found that the formation of this 
complex was inhibited by addition of 50-fold excess of unlabeled HDM2 mRNA (MP4 probe) 
(Figure 23, Lane 2 and 3). This competition assay was performed to determine the specificity 
of the binding complex. These data indicate that an RNA-binding protein is interacting with 
this HDM2 MP4 probe but still did not know the identity of the RNA binding protein. We 
suspected hnRNP A1 to be the RNA binding protein interacting with this probe based on our 
previous findings. Previous studies have reported that hnRNP A1 binds to exonic sequences to 
regulate the alternative splicing of Rac1, an alternatively spliced isoform of the small GTPase 
Rac1 127. Based on these findings, we performed biotin pull down assay, a method that 
combines incubation of RNA probe with nuclear protein extract followed by immune-
precipitation of this complex which has proven useful in demonstrating interactions of 
specific RNA binding proteins and their target RNA. We decided to perform this biotin pull 
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down assay to provide experimental evidence that hnRNP A1 is fact interacting with 
Biotinlabeled HDM2 mRNA MP4 probe.  
 
B. Identification of RNA binding protein responsible for association with the HDM2 
RNA probe (MP4). 
          To determine if hnRNP A1 was the RNA binding protein that is interacting with HDM2 
RNA probe observed in the complex shown in Figure 23, we performed a biotin pull down 
assay followed by western blotting. This technique consists of selectively extracting a 
biotinylated-RNA-protein complex using streptavidin. We performed the biotin pull down 
assay by first incubating hnRNP A1 antibody (4B10) with Dynabeads Myone streptavidin.  
We also incubated Biotinlabeled HDM2 mRNA (MP4 probe) or Biotinlabeled B-actin RNA probe 
with IMR-90 cell lysate. Following incubation, we added the biotinylated RNA probes and 
protein lysates mixtures to Myone streptavidin beads coated with the 4B10 monoclonal 
antibody (specific for hnRNP A1). This mixture was incubated overnight. We performed 
western blot analysis as described in Material and Methods to investigate the interaction 
between Biotinlabeled HDM2 mRNA and hnRNP A1. As shown in Figure 24b, hnRNP A1 was 
identified as the RNA binding protein to directly associate with Biotinlabeled HDM2 mRNA 
(MP4 probe). The direct association between hnRNP A1 and Biotinlabeled HDM2 mRNA 
appears to be specific, since these interactions were not observed with similar RNA binding 
protein hnRNP A0. Furthermore, associations between hnRNP A1 and negative control 
Biotinlabeled B-actin were not observed. These results demonstrate that hnRNP A1 has specific 
binding to Biotinlabeled HDM2 mRNA (MP4 probe). 
! ! PR!
 
Figure 21. PESX analysis. PESX (Putative exon splicing enhancer/silencers) is a utility that 
can predict regions of an mRNA that may be involved in exon splicing to enhance the 
inclusion or exclusion of an exon. In addition to identifying the putative splicing regulatory 
sequences, the sequences were also scanned for putative hnRNP A1 binding sites [UAG 
(G/A)] on the basis of known binding sites and these sequences are marked in enlarged letters 





Figure 22. pCR II digestion. MP4 insert was released from the pCR 2.1 plasmid following 
digestion with EcoRI and BamHI restriction enzymes. Following digestion, run un-cut and cut 
pCR 2.1 DNA was electrophorosed on a 1% Agarose gel at constant 80V for 40 minutes to 
detect the presence of the insert.  
Uncut pCR2.1  Cut pCR2.1 






Figure 23. RNA electrophoretic mobility shift assay of hnRNP A1 and HDM2 mRNA 
probe. RNA-EMSA was performed by incubating in vitro transcribed biotin labeled HDM2 
probe with 0.5 ug of nuclear protein extract prepared from IMR-90 cells. The migration of the 
free probe, and shifted complexes are indicated with the arrow.  
RNA probe 
RNA probe + 
protein extract 









Figure 24. Biotin pull down assay of hnRNP A1 with HDM2 transcript (MP4).  
A. Schematic representation of full length HDM2 and mini-protein “MP” fragments of HDM2 
MP1-MP4. B. The interaction between hnRNP A1 and biotinlynated HDM2 mRNA (MP4) 
was examined by biotin pull down assay. Biotinylated HDM2 and actin probes were 
incubated with IMR-90 cell lysates. Interactions were analyzed by western blotting. The 
protein-RNA probe-streptavidin complexes were subjected to electrophoresis on a 12% SDS-
PAGE. The 4B10 monoclonal antibody and anti-actin antibody were used to detect hnRNP 












activity, and loss of Mdm2 results in an active p53 that has
dire consequences to the cell and embryo.
Gene Structure and Protein Motifs
Both the mdm2 gene and its human counterpart, MDM2 ,
consist of 12 exons that can generate many different proteins.
There are two different promoters, the second of which is
responsive to p53. These promoters generate two proteins, the
full-length p90 and a shorter protein p76 that initiates at an
internal ATG (19–21 and see review by M. E. Perry [January
2004 issue, MDM2: Part II] for details). p76 is missing part of
the p53-binding domain (Fig. 1) and it can act as a dominant
negative inhibitor of p90 and activate p53. Alternative splicing
of MDM2 and the generation of short proteins also occurs in
many human and mouse tumors. Numerous short MDM2
proteins which encode the carboxyl terminus of MDM2 have
been identified (22 and see review by Bartel et al. in January
2004 issue, MDM2: Part II). In humans, MDM2-A and
MDM2-B are the major splice variants that delete exons 4–9
and 4–11, respectively. Neither product contains the p53-
binding motif. MDM2-B, also named MDM2-ALT1, interacts
with full-length MDM2 and sequesters it in the cytoplasm
(23). Multiple spliced variants were also present in murine
tumors (24). Thus, these short MDM2 proteins may function
as dominant negatives inhibiting the function of full-length
MDM2 and thus amplifying the activity of p53. A vexing
question, however, is why tumor cells would make these
proteins in the first place. One possibility is that they represent
a signal left over from when the cell was trying to maintain
control. The presence of these proteins and subsequent
activation of p53 would provide, however, an impetus for
mutati g 53 and may be the reason some cancers have both
high levels of MDM2 and mutations in p53.
The p53 interaction domain is encoded by the amino
terminal 100 amino acids of MDM2. This domain binds the
amino terminal transactivation domain of p53. Thus, even if
MDM2 cannot degrade p53, it interferes with the ability of
p53 to interact with the transcription machinery. Other motifs
include a nuclear localization signal and a nuclear export
signal. These signals shuttle MDM2 back and forth between
the cytoplasm and the nucleus and provide yet another means
by which p53 activity is tightly regulated (25, 26). Amino
acids 464–471 can function as a nucleolar localization signal
(27), although the biological significance of this regulation
is unclear. The central acidic domain of MDM2 is necessary
for interaction with the ribosomal protein L5, and with
p300/CBP (CREB-binding protein). Recently, this domain
was found to contribute to p53 degradation because an
MDM2 mutant lacking part of this domain ubiquitinated p53
well but failed to degrade p53 (28, 29). Downstream of the
acidic domain is a zinc finger domain of unknown function
followed by the RING domain, which has already been
discussed.
A p53/MDM2 Regulatory Feedback Loop
p53 transcriptionally activates many target genes, one of
which is the mdm2 gene (21, 30). p53 binds the mdm2 P2
promoter and transcriptionally up-regulates mdm2 expression.
Because Mdm2 inhibits p53 activity, this forms a negative
feedback loop that tightly regulates p53 function. In turn,
decreased p53 activity results in decreased Mdm2 to
constitutive levels. MDM2 can also ubiquitinate itself and
induce its own degradation (12, 13). This is yet another
example of a different regulatory mechanism that titrates the
levels of MDM2 and therefore p53 very precisely. So how
does p53 escape the detrimental effects of binding MDM2?
Upon DNA damage, p53 is posttranslationally modified to
inhibit interactions with MDM2. Several kinases also
phosphorylate MDM2 and modulate interactions with p53
(18a, 30a). This ability of p53 to regulate mdm2 provides a
feedback loop with an important role in regulating cell cycle
progression and apoptosis (30b).
FIGURE 1. Structure ofmdm2 gene and protein.mdm2 gene consists of 12 exons and two p53 responsive elements (p53 RE ) in intron 1. Two promoters
are shown by arrows . Full-length MDM2 p90 is translated from the first start codon ATG in exon 3 and the short form, p76, is translated from the second ATG
in exon 4. Two major alternative splice variants in the human genes MDM2-A and MDM2-B are shown. Full-length Mdm2 and known motifs are also
represented. NLS, nuclear localization signal; NES, nuclear export signal; Zn-finger, zinc-finger domain; NoLS, nucleolar localization signal; RING-finger,
ring-finger domain. The numbers above the drawings denote amino acid numbers and roman numerals are exon numbers.
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4.3 Discussion and summary  
          In the present study, our findings suggests that hnRNP A1, an RNA binding protein 
binds to Biotinlabeled HDM2 mRNA probe (MP4) which includes part of exon 11 and exon 12 
of HDM2 mRNA as shown in Figure 24a. REMSA and UV-cross linking experiments to 
covalently link complexes of Biotinlabeled HDM2 mRNA (MP4) incubated with protein lysates 
revealed that the migration of HDM2 RNA probe detected a Protein-RNA complex (Figure 
23). This complex could be competitively inhibited (Figure 23) by the presence of an excess 
amount of non-labeled HDM2 mRNA probe (Figure 23 compare lane 2 and 3) suggesting a 
specific protein-RNA interaction. Previous approaches as those used by S.J. Park et al. 
demonstrated with a biotin pull down assay that hnRNP A1 associates with Drp1 mRNA via 
3’ UTR 115. We applied this approach to show that hnRNP A1 binds to the HDM2 mRNA 
(MP4 probe) and that this binding was specific as hnRNP A0 did not bind to HDM2 MP4 
probe (Figure 24). Our sequencing data of the HDM2 (MP4) reveals that it contains a putative 
G/AGAAG nucleotide sequence similar to the 5’AGAAG 3’ high affinity binding site found 
in the purine-rich 3’ splice site of c-src mRNA exon N1 116. These AG-rich motifs have high-
affinity binding sites for, hnRNP A1, have also been found in c-H-ras and HIV1 TAT pre-
mRNAs  22,117. Overall, our RNA-protein interaction experiments data strongly suggest that 
hnRNP A1 interacts with a region of HDM2 transcript corresponding to its 3’ UTR. It has 
been previously reported that RNA binding protein RNPC1, binds to the 3’UTR region in 
HDM2 transcripts and inhibits its expression 11. Thus, the HDM2 3’ UTR is bound by 
different RNA binding proteins that might either repress or induce its expression. For 
instance, HuR, a RNA binding protein has been shown to bind and stabilize HDM2 via its 3’ 
UTR. From earlier studies, we found that hnRNP A1 modulated the mRNA expression of 
! ! QN!
HDM2. Therefore, the MP4 sequence that hnRNP A1 binds to may be partially contributing 
to this modulation.  
          Under stressful conditions, the HDM2 transcript is subject to alternative splicing 
producing splice variants in both normal and cancer tissues 24. hnRNP A1 and SRF1, formerly 
SF2/ASF, are two well known splicing factors reported to regulate UV-induced alternative 
splicing of HDM2 118,119. For instance, it was demonstrated that when HDM2 was subjected to 
genotoxic stress, it resulted in the generation of HDM2-B, a frequently observed splice variant 
of HDM2 118. A recent study examining the regulation of HDM2 alternative splicing found 
that exon 11 of a HDM2 mini-gene consisting of Exons 3,11 and 12 of HDM2 contains a 
binding site for SRF1. More importantly, it was found that under stress stressful conditions, 
the binding of SRF1 to Exon 11 is increased and regulates the alternative splicing HDM2. Of 
note, the mini-protein  “MP4”, we used to synthesize the HDM2 transcript to study HDM2 
mRNA interaction with hnRNP A1 consists of exon 11 and 12 of HDM2 suggesting that 
hnRNP A1 could potentially regulate the alternative splicing of HDM2. As previously 
mentioned in chapter 1, hnRNP A1 has been reported to modulate the alternative splicing of 
several transcripts 1. It was recently published that the treatment of HaCaT cells with UV 
resulted in the alternative splicing of HDM2 producing HDM2-B 118. It would be interesting 
to determine our studies results have relevance in tumorigenesis. For instance, it has been 
demonstrated that the HDM2-B isoform binds to full length HDM2 and inhibits the 
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